TW552143B - Adhesive composition, and moisture-permeable adhesive tape, adhesive medical composition and adhesive medical tape containing same - Google Patents

Adhesive composition, and moisture-permeable adhesive tape, adhesive medical composition and adhesive medical tape containing same Download PDF

Info

Publication number
TW552143B
TW552143B TW088112931A TW88112931A TW552143B TW 552143 B TW552143 B TW 552143B TW 088112931 A TW088112931 A TW 088112931A TW 88112931 A TW88112931 A TW 88112931A TW 552143 B TW552143 B TW 552143B
Authority
TW
Taiwan
Prior art keywords
adhesive
weight
composition
tape
moisture
Prior art date
Application number
TW088112931A
Other languages
Chinese (zh)
Inventor
Eiichi Kitazono
Hiroyoshi Minematsu
Takeyuki Kawaguchi
Takanori Miyoshi
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Application granted granted Critical
Publication of TW552143B publication Critical patent/TW552143B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J11/00—Features of adhesives not provided for in group C09J9/00, e.g. additives
    • C09J11/02—Non-macromolecular additives
    • C09J11/06—Non-macromolecular additives organic
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J133/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
    • C09J133/04—Homopolymers or copolymers of esters
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J133/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
    • C09J133/04—Homopolymers or copolymers of esters
    • C09J133/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
    • C09J133/08—Homopolymers or copolymers of acrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J7/00—Adhesives in the form of films or foils
    • C09J7/30—Adhesives in the form of films or foils characterised by the adhesive composition
    • C09J7/38—Pressure-sensitive adhesives [PSA]
    • C09J7/381—Pressure-sensitive adhesives [PSA] based on macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C09J7/385—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J9/00—Adhesives characterised by their physical nature or the effects produced, e.g. glue sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2666/00—Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
    • C08L2666/28—Non-macromolecular organic substances
    • C08L2666/34—Oxygen-containing compounds, including ammonium and metal salts
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J2301/00—Additional features of adhesives in the form of films or foils
    • C09J2301/30—Additional features of adhesives in the form of films or foils characterized by the chemical, physicochemical or physical properties of the adhesive or the carrier
    • C09J2301/302—Additional features of adhesives in the form of films or foils characterized by the chemical, physicochemical or physical properties of the adhesive or the carrier the adhesive being pressure-sensitive, i.e. tacky at temperatures inferior to 30°C

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Adhesive Tapes (AREA)

Abstract

An adhesive composition of this invention includes 50 to 90 wt% of an acrylic adhesive including at least one member selected from polymers and copolymers of (meth)acrylic acids and alkyl(meth)acrylates, 2.5 to 50 wt% of a liquid component containing at least one multi-hydric alcohol selected from glycerol, propylene glycol, 1,3-butylene glycol, diglyserol, dipropylene glycol, 1,2,6-hexane triol, sorbitol, polyethylene glycol and pentaerythritol, and 0.01 to 10 wt% of a mono-, di- or tri-valence metal salt of a C8-C18 hydrocarbon group-containing fatty acid, in which fatty acid metal salt, the fatty acid having a C8-C18 hydrocarbon group is selected from lauric acid, myristic acid, stearic acid and oleic acid and the mono-, di- or tri-valence metal is selected from sodium, magnesium, zinc and aluminum, has high pressure-sensitive adhesive property, cohesive property and moisture-permeability, and is useful for preparing an adhesive medical composition containing a medical agent and having the same properties as those of the adhesive composition, and for producing an adhesive tape having adhesive composition layer coated on a support and exhibiting a high moisture-permeability, and an adhesive medical tape having an adhesive medical composition coated on a support and exhibiting a high moisture-permeability and a high endermic absorption of medical agent.

Description

552143 A 7 B7 五、發明説明（1 ) 本發明係有關黏著劑組成物以及含此黏著劑組成物之 透濕性粘膠及含該黏著性組成物之黏著性藥劑組成物以及 含該黏著性藥劑組成物之膠帶製劑者。 更詳細者係有關本發明對人體肌膚具有良好粘著性， 且具有高度透濕性之黏著劑組成物及具有含此黏著性組成 物之粘著層，具高度皮膚粘著性、良好透濕性之透濕性膠 帶’及含該黏著性組成物之黏著性藥劑組成物，以及具有 含該黏著性藥劑組成物之黏著藥劑層之高度皮膚粘著性、 良好透濕性之膠帶製劑者。 先行技術中積極開發對人體肌膚具良好粘著性，且具 適當之透濕性之黏著劑組成物，以及黏著性藥劑組成物以 及具有含該黏著性組成物之粘著層之透濕性膠帶及藥劑， 特別是，爲透過皮膚投與體內之藥劑所含有具粘著性藥劑 層之膠帶製劑者。做爲該黏著劑組成物及黏著性藥劑組成 物之粘著劑者於膠帶製劑用時可使用橡膠系、聚矽氧系、 丙烯系、醋酸乙烯酯系、乙烯醚系等被使用之。其中又以 丙烯系之皮膚刺激性小、成本低爲較理想者。又，含經皮 吸收性藥劑之膠帶製劑中，爲提高藥劑之皮膚轉移性，務 必將此膠帶製劑確實貼於皮膚面，惟，粘著力太強時，由 皮膚剝離膠帶製劑時易出現角質層之剝離，因此，皮膚刺 激變大。爲解決此問題於開發丙烯系粘著製劑中，將此粘 著於皮膚時使皮膚觸感柔軟，又，爲提高藥物之經皮吸收 性，使含多量液體成份於粘著劑中等進行改良之。例如“ 山梨聚糖酯、脂肪酸酯類、以及多價醇等公知者爲具有促 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） 裝-- (請先閱讀背面之注意事項再填寫本頁) 、11 經濟部智慧財產(工消費合作社印製 -4- 552143 A7 B7 五、發明説明（2 ) 進藥劑之經皮吸收之效果，丙烯系粘著劑中含有該山梨聚 糖酯等之藥劑經皮吸收促進劑之膠帶藥劑被公開（特開平 (請先閱讀背面之注意事項再填寫本頁) 1 — 233212號公報、特開平1 — 233213號公 報、特開平2 - 1 9 6 7 1 4號公報及特開平2 - 2 3 3 6 1 7號公報）。惟，此等已知藥劑經皮吸收促進 劑含於粘著劑中後，其結果降低粘著劑之凝聚力、於皮膚 貼著、剝離時，殘留部份粘著層，亦即，產生殘餘粘糊， 又，含該藥劑經皮吸收促進劑之液體成份有產生由粘著層 滲出等問題。 針對改善丙烯系粘著劑凝聚力之方法，目前仍有多樣 被討論之。其一之方法如公知者有於粘著層進行紫外線照 射、電子線照射、以及放射線照射等物理方法者，惟，此 等方法，如：紫外線照射等易引起藥劑分解，因此，做爲 醫療用粘著劑之處理方法爲不理想者。 經濟部智慧財產笱員工消費合作社印製 爲改善丙烯系粘著劑之凝聚力另種方法有化學方法者 ，做爲此法者有特開平3 - 2 2 0 1 2 0號公報被公開之 金屬醇鹽、金屬螫合化合物，及/或異氰酸酯化合物與丙 烯系粘著性聚合物中之羧基交聯反應之方法者。其他亦有 金屬鹽、有機過氧化物、聚胺酯化合物、及/或多官能性 化合物等爲改善丙烯系粘著劑之凝聚力使用之而取得者爲 公知者。惟’金屬醇鹽、金屬螫合化合物、異氰酸酯化合 物、聚胺酯化合物、及/或多官能性化合物等與具有官能 基之藥劑共同使用後，將降低兩者相互作用引起藥劑經皮 吸收性，更無法提昇粘著劑凝聚力效果之問題產生。 ^紙張尺度適用中國國家標準("CNS ) A4規格（210X297公釐） '~~' -5 - 552143 A7 B7 五、發明説明（3 ) (請先閲讀背面之注意事項再填寫本頁) 更且’爲用於藥劑經皮吸收之膠帶製劑雖然長時間持 續投與之藥劑，於口服時引起胃腸障礙之消炎鎭痛，或， 初次通過肝臟幾乎被分解之藥劑投與極爲優異，惟，長時 間持續貼附後，易產生皮膚發炎、搔癢之問題。 爲改善該皮膚發炎之預防性，由先行技術討論盡可能 減少粘著劑中殘存單量體、殘存溶媒之含量，而基本上以 提高貼附劑透濕性（水份散發性）、抑制貼附部皮膚之悶 濕（水份散發不良）爲宜。惟，提高透濕性、減少貼附劑 之密封性後，藥劑之經皮吸收量則極端下降，而造成無法 充份達成膠帶製劑之原有目的之不理想狀態。爲維持所期 待之藥劑經皮吸收量，可使用水份不滲透性之粘著劑，或 具有如丙烯系粘著劑之透濕性粘著劑使用時，如P E T薄 膜等實質上無透濕性或低支撑基材於透濕性粘著層合倂使 用之。 經濟部智慧財產局員工消費合作社印製 做爲皮膚發炎較小之膠帶製劑者公知者有糊劑。此爲 含有聚丙烯酸鹽或聚乙烯醇之透濕性含水凝膠粘著層如不 織布等積層於透氣性、伸縮性均良好之支撑體者。於含凝 膠粘著層以含 Indomethasin 、可多普落菲做爲藥效成份 之糊劑現階段被廣泛做爲消炎鎭痛糊劑使用之。惟，糊劑 對於皮膚接合力弱，因此，爲保持貼附務必進行補助手段 ，另外，溫度變高易造成凝膠之粘腻等缺點，因此被提出 以消炎鎭痛膠帶劑取代該消炎鎭痛糊劑因應實用化（ W 0 93/04677號明細書，及W〇 9 6/ 〇8 2 4 5號明細書）。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -6- 552143 A7 B7 五、發明説明（4 ) (請先閲讀背面之注意事項再填寫本頁) 此膠帶製劑之粘著層可使用凝聚力高、接合力亦高之 橡膠系粘著劑，又做爲支撑體者可藉由使用伸縮性、透氣 性均高之布（較佳者爲針織布）後，於手肘等彎曲部位貼 附膠帶製劑可維持之。 惟’該橡膠系粘著劑其實質上無透濕性，因此該膠帶 製劑犧牲透濕性後而提昇藥劑之經皮吸收性者。又，一般 橡膠系粘著劑中，務必添加粘著附與劑等之比較低分子量 化學物質，添加此添加劑係皮膚發炎之起因者。 膠帶製劑之粘著層中，除上述橡膠系粘著劑之外，如 聚石夕氧系、丙烯系、醋酸乙烯酯系及乙烯醚系粘著劑具強 力凝聚力與充份皮膚粘著性之粘著劑爲一般被使用之。其 中又以無須添加氧化防止劑及粘著附與劑（Taxifire ) 之丙烯系粘著劑者爲較理想者。惟，此時亦以未具實質透 濕性之聚酯薄膜等做爲支撑基材使用，犧牲皮膚水份散發 性’提昇藥劑之經皮吸收性被預測者。 經濟部智慧財產局員工消費合作社印製 又’公知者，山梨聚糖酯具有藥物之促進皮膚吸收之 效果者’目前爲止，亦有醇鹽與山梨聚糖酯倂用之糊劑及 乳霜劑被提出（特開昭6 1 - 1 2 6 2 1號公報、專利第 2 6 0 4 0 9 7號公報、特開昭6 3 — 1 0 4 9 1 3號公 報、以及特開昭6 3 - 2 3 0 6 4 0號公報）。更被公開 者如含於丙烯系粘著劑之山梨聚糖酯之膠帶製劑（特開平 1 一 2 3 3 2 1 2號公報、特開平1 — 2 3 3 2 1 3號公 報、特開平2 - 1 9 6 7 1 4號公報、特開平2 - 2 3 3 6 1 7號公報）。惟，此等已知膠帶製劑中，其支 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） 552143 A7 _ __B7 五、發明説明（5 ) 撑基材使用非透濕性之聚對苯二甲酸乙酯薄膜等者，做爲 製劑者無法確保必要之透濕性。由上述說明截至目前含顯 示高透濕性、高經皮吸收性、以及高凝聚力之油性黏著劑 組成物之膠帶製劑尙未出現。 本發明目的係爲提供對於人體皮膚之高粘著性、高凝 聚力與適度之透濕性、經皮吸收性藥劑實用上具有充份之 醫藥適合性，對人體皮膚刺激性小，極低黏著性組成物， 含此黏著性組成物，因此具凝聚力高之粘著層，粘著剝離 時不產部份殘留之粘著層，或極少產生，具高度透濕性之 透濕性黏著膠帶，具有該黏著劑組成物與藥劑，特別是含 經皮吸收性藥劑之黏著性藥劑組成物及該黏著性藥劑組成 物，且具有高凝聚力之藥劑粘著層、粘著剝離時，無殘留 藥劑黏著層於皮膚，或極少，具有高度透濕性之黏著膠帶 製劑者。 該目的可藉由本發明達成之。 本發明黏著劑組成物係由5 0〜9 0重量％之丙烯系 黏著劑與2 · 5〜5 0重量％之多價醇液體成份以及含 〇·01〜10重量％之8〜18個碳原子之烴基脂肪酸 與1〜3價之金屬所組成之含有脂肪酸金屬鹽者。 本發明透濕性膠帶係形成於支撑體與其一表面上，且 具有含本發明黏著性組成物之粘著層者。 本發明黏著性藥劑組成物針對該本發明黏著劑組成物 與此黏著劑組成物重量爲含〇 · 〇 5〜4 0重量％之藥劑 者。 i紙ϋ度適用中國國家標準（CNS ) A4規格（210^ 297公釐) " ’ -- -8- (請先閱讀背面之注意事項再填寫本頁) 裝- 訂 經濟部智慧財產局員工消費合作社印製 552143 A7 --~----— _B7___ 五、發明説明（6 ) 本發明膠帶製劑係形成於支撑體與其一表面上，且 含該本發明黏著性藥劑組成物之黏著藥劑層者。 〔發明實施之最佳形態〕 本發明黏著性組成物係由5 0〜9 0重量份之丙烯系 黏著劑與2 . 5〜5 0重量份之多價醇液體成份與具有 〇 · 〇 1〜1 0重量份之8〜1 8個碳原子之烴基脂肪酸 與1〜3價之金屬所組成之脂肪酸金屬鹽者。 霞亥丙烯系黏著劑係選自至少含1種丙烯酸、甲基丙烯 酸、丙烯酸烷酯、甲基丙烯酸烷酯之各聚合物，及此等中 之至少1種之共聚物者。該共聚物中，做爲選自丙烯酸、 甲基丙烯酸、丙烯酸烷酯及甲基丙烯酸烷酯至少1種之共 聚乙烯性不飽和共聚用單體者，如：乙烯醇、2 -羥基（ 甲基）丙烯酸酯、羥基丙基（甲基）丙烯酸酯之含氫氧基 之單量體；（甲基）丙烯酸、衣康酸、巴豆酸、馬來酸、 馬來酸酐、延胡索酸類之羧基含有單量體；苯乙烯磺酸、 烯丙磺酸、硫代丙烯酸丙酯、（甲基）丙烯醯氧萘磺酸、 (甲基）丙烯醯胺甲基丙磺酸、丙醯氧苯磺酸類之次硫基 含有單量體；二甲胺乙基丙烯酸鹽、乙基吡咯烷酮類之胺 基含有單量體；（甲基）丙烯酸羥基乙酯、（甲基）丙烯 酸羥基丙酯類之羥基含有單量體；（甲基）丙烯醯胺、二 甲基（甲基）丙烯醯胺、正-丁基（甲基）丙烯醯胺、四 甲基丁基（甲基）丙烯醯胺、正一羥甲基（甲基）丙烯醯 胺、乙氧基甲基（甲基）丙烯醯胺類之醯胺基含有丙烯系 本紙張尺度適用中國國家標準（CNS) Α4規格（21〇Χ297公釐） (請先閲讀背面之注意事項再填寫本頁) -裝·552143 A 7 B7 V. Description of the invention (1) The present invention relates to an adhesive composition and a moisture-permeable adhesive containing the adhesive composition, an adhesive pharmaceutical composition containing the adhesive composition, and the adhesive property. Tape preparation of pharmaceutical composition. In more detail, the present invention relates to an adhesive composition having good adhesion to human skin and having high moisture permeability, and an adhesive layer containing the adhesive composition, which has high skin adhesion and good moisture permeability. A moisture-permeable adhesive tape ', an adhesive pharmaceutical composition containing the adhesive composition, and a tape preparation having a high degree of skin adhesion and a good moisture permeability of the adhesive pharmaceutical layer containing the adhesive pharmaceutical composition. In the prior art, active development of an adhesive composition having good adhesion to human skin and appropriate moisture permeability, an adhesive pharmaceutical composition, and a moisture-permeable tape having an adhesive layer containing the adhesive composition And medicaments, in particular, those which are administered to the body through the skin, and which are tape preparations with an adhesive medicament layer contained in the medicament. As the adhesive composition of the adhesive composition and the adhesive agent composition, rubber-based, silicone-based, propylene-based, vinyl acetate-based, vinyl ether-based, etc. can be used when the tape preparation is used. Among them, acrylic skin has less irritation and lower cost. In addition, in the case of a tape preparation containing a transdermal absorbent agent, in order to improve the skin transferability of the agent, the tape preparation must be affixed to the skin surface. However, if the adhesive force is too strong, the stratum corneum tends to appear when the tape preparation is peeled from the skin It is peeled, so that skin irritation becomes large. In order to solve this problem, in the development of acrylic adhesive preparations, the skin is soft to the touch when it is adhered to the skin, and in order to improve the transdermal absorption of the drug, it is improved by containing a large amount of liquid ingredients in the adhesive. . For example, "Sorbitan esters, fatty acid esters, and polyhydric alcohols are known to those who have promoted the size of this paper to apply the Chinese National Standard (CNS) A4 specification (210X297 mm)."-(Please read the precautions on the back before Fill in this page), 11 Intellectual property of the Ministry of Economic Affairs (printed by the Industrial and Consumer Cooperatives -4- 552143 A7 B7) 5. Description of the invention (2) The effect of transdermal absorption of pharmaceuticals, the sorbent is contained in acrylic adhesives The tape drug for the percutaneous absorption enhancer is disclosed (Japanese Patent Application Laid-Open (please read the precautions on the back before filling out this page) 1-233212, JP 1-233213, JP 2-1 9 6 7 1 4 and Japanese Patent Application Laid-Open No. 2-2 3 3 6 1 7). However, when these known pharmaceutical agents for percutaneous absorption promotion are contained in the adhesive, as a result, the cohesive force of the adhesive is reduced, and When the skin is attached or peeled off, the remaining part of the adhesive layer, that is, a residual sticky paste is generated, and the liquid component containing the agent for the percutaneous absorption enhancer has problems such as exudation from the adhesive layer. The method of cohesiveness of the agent is still at present Various methods have been discussed. One method is known as physical methods such as ultraviolet irradiation, electron beam irradiation, and radiation irradiation on the adhesive layer. However, these methods, such as ultraviolet irradiation, can easily cause the decomposition of pharmaceuticals. Therefore, the treatment method for medical adhesives is not ideal. Printed by the Intellectual Property of the Ministry of Economic Affairs and the Consumer Consumption Cooperative Society to improve the cohesiveness of propylene-based adhesives. Another method is a chemical method. Japanese Patent Application Laid-Open No. 3-2 2 0 1 2 0 discloses a method for crosslinking reaction of a metal alkoxide, a metal chelate compound, and / or an isocyanate compound with a carboxyl group in a propylene-based adhesive polymer. Others are also available Metal salts, organic peroxides, polyurethane compounds, and / or polyfunctional compounds are well-known as those obtained in order to improve the cohesiveness of propylene-based adhesives. However, 'metal alkoxides, metal chelate compounds, and isocyanate compounds are known. , Polyurethane compounds, and / or polyfunctional compounds are used together with functional agents to reduce the interaction between them The problem of skin absorptivity can not improve the cohesive effect of the adhesive. ^ The paper size applies the Chinese National Standard (" CNS) A4 specification (210X297 mm) '~~' -5-552143 A7 B7 V. Description of the invention ( 3) (Please read the precautions on the back before filling out this page) and 'is a tape preparation for transdermal absorption of the drug. Although the drug is continuously administered for a long time, it may cause anti-inflammatory pain in gastrointestinal disorders when taken orally, or, The administration of the drug that is almost decomposed by the liver for the first time is extremely excellent, but after long-term continuous application, it is easy to cause skin inflammation and itching. In order to improve the prevention of skin inflammation, the prior art discusses reducing the adhesive as much as possible. The content of the residual single body and the residual solvent is basically to improve the moisture permeability of the patch (moisture dispersibility) and to suppress the moistness of the skin at the patch (poor moisture dispersal). However, after improving the moisture permeability and reducing the sealability of the patch, the percutaneous absorption of the drug is extremely reduced, resulting in an unsatisfactory state in which the original purpose of the tape preparation cannot be fully achieved. In order to maintain the desired transdermal absorption of the agent, a moisture-impermeable adhesive or a moisture-permeable adhesive such as an acrylic adhesive can be used. When used, such as a PET film, there is substantially no moisture permeability. It is used as a base material with low or strong support in moisture-permeable adhesive layer. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. As a tape preparation with less skin inflammation, it is known to have a paste. This is a moisture-permeable hydrogel adhesive layer containing polyacrylate or polyvinyl alcohol, such as a non-woven fabric, laminated on a support having good air permeability and stretchability. In the gel-containing adhesive layer, a paste containing Indomethasin and Cidoprofil as a medicinal ingredient is currently widely used as an anti-inflammatory and pain paste. However, the paste has weak adhesion to the skin. Therefore, it is necessary to provide subsidies to maintain the adhesion. In addition, the temperature may easily cause the stickiness of the gel, such as shortcomings. Therefore, it has been proposed to replace the anti-inflammatory pain pain tape with an anti-inflammatory pain pain tape. The paste should be put into practical use (Details No. W 0 93/04677 and Details No. W09 6/008 2 45). This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) -6- 552143 A7 B7 V. Description of invention (4) (Please read the precautions on the back before filling this page) Adhesive layer of this tape preparation Can use rubber adhesive with high cohesive force and high bonding force. As a supporter, you can use elastic cloth (knitted cloth) with high elasticity and air permeability, and then bend it on the elbow. A site-applied tape preparation can maintain it. However, since this rubber-based adhesive has substantially no moisture permeability, the adhesive tape preparation sacrifices moisture permeability and improves the percutaneous absorption of the drug. In addition, in general rubber-based adhesives, it is necessary to add comparatively low-molecular-weight chemical substances such as adhesives, and the addition of these additives is a cause of skin inflammation. In the adhesive layer of the tape preparation, in addition to the above-mentioned rubber-based adhesives, such as polyoxetane-based, propylene-based, vinyl acetate-based and vinyl ether-based adhesives have strong cohesion and sufficient skin adhesion Adhesives are generally used. Among them, a propylene-based adhesive agent without the need to add an oxidation inhibitor and an adhesive agent (Taxifire) is preferable. However, at this time, a polyester film or the like that does not have substantial moisture permeability is used as a supporting substrate, and the skin's water-emission property is sacrificed to improve the transdermal absorption of the agent. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs and "Known, sorbitan esters have the effect of promoting the absorption of skin by drugs" So far, there are also pastes and creams for alkoxides and sorbitan esters. Proposed (Japanese Patent Application Laid-Open No. 6 1-1 2 6 2 1; Patent Japanese Patent No. 2 0 4 0 9 7; Japanese Patent Laid-Open No. 6 3 — 1 0 4 9 1 3; Japanese Patent Laid-Open No. 6 3 -2 3 0 6 4 0). Also disclosed are tape preparations of sorbitan esters containing acrylic adhesives (Japanese Patent Application Laid-Open No. 1-2 3 3 2 1 2, Japanese Patent Application Laid-Open No. 1-2 3 3 2 1 3, Japanese Patent Application Laid-open No. 2 -1 9 6 7 1 4 and Japanese Patent Application Laid-Open No. 2-2 3 3 6 1 7). However, in these known tape preparations, the paper size of the paper is applicable to the Chinese National Standard (CNS) A4 (210X 297 mm) 552143 A7 _ __B7 V. Description of the invention (5) The supporting substrate uses non-moisture-permeable Polyethylene terephthalate films, etc., cannot provide necessary moisture permeability as a preparation. From the above description, a tape preparation containing an oily adhesive composition showing high moisture permeability, high transdermal absorption, and high cohesiveness has not yet appeared. The purpose of the present invention is to provide high adhesiveness to human skin, high cohesion and moderate moisture permeability, and transdermal absorbent medicaments with practically adequate medical suitability, little irritation to human skin, and extremely low adhesion. The composition contains this adhesive composition, so it has an adhesive layer with high cohesive force, and does not produce a part of the adhesive layer that remains when the adhesive is peeled off, or it rarely occurs. A moisture-permeable adhesive tape with high moisture permeability has The adhesive composition and the medicament, especially the adhesive medicament composition containing the transdermal absorbent medicament and the adhesive medicament composition, and the medicament adhesive layer with high cohesive force, and there is no residual medicament adhesive layer when the adhesive is peeled off To skin, or very few, highly adhesive tape preparations. This object can be achieved by the present invention. The adhesive composition of the present invention is composed of 50 to 90% by weight of a propylene-based adhesive, 2.5 to 50% by weight of a polyvalent alcohol liquid component, and 8 to 18 carbons containing 0.01 to 10% by weight. A fatty acid metal salt composed of an atomic hydrocarbon-based fatty acid and a 1-3 valent metal. The moisture-permeable adhesive tape of the present invention is formed on a support and one surface thereof, and has an adhesive layer containing the adhesive composition of the present invention. The adhesive pharmaceutical composition of the present invention is directed to those containing the adhesive composition of the present invention and the adhesive composition in an amount of 0.5 to 40% by weight. i Paper is suitable for China National Standard (CNS) A4 specification (210 ^ 297 mm) " '--8- (Please read the precautions on the back before filling this page) Printed by the consumer cooperative 552143 A7-~ ------ _B7___ V. Description of the invention (6) The adhesive tape preparation of the present invention is formed on the support and one surface thereof, and contains the adhesive agent layer of the adhesive agent composition of the present invention. By. [The best form for carrying out the invention] The adhesive composition of the present invention is composed of 50 to 90 parts by weight of a propylene-based adhesive and 2.5 to 50 parts by weight of a polyvalent alcohol liquid component and has 〇 · 〇1 ~ 10 parts by weight of a fatty acid metal salt composed of a hydrocarbon-based fatty acid of 8 to 18 carbon atoms and a metal of 1 to 3 valence. Xiahai propylene-based adhesives are selected from polymers containing at least one type of acrylic acid, methacrylic acid, alkyl acrylate, and alkyl methacrylate, and copolymers of at least one of these. The copolymer is a copolymerizable unsaturated comonomer selected from at least one of acrylic acid, methacrylic acid, alkyl acrylate, and alkyl methacrylate, such as vinyl alcohol, 2-hydroxy (methyl ) Hydroxyl-containing monomers of acrylate and hydroxypropyl (meth) acrylate; carboxyl groups of (meth) acrylic acid, itaconic acid, crotonic acid, maleic acid, maleic anhydride, and fumaric acid Volumetric body; styrene sulfonic acid, allyl sulfonic acid, propyl thioacrylate, (meth) acrylic acid naphthalenesulfonic acid, (meth) acrylamide methylpropanesulfonic acid, propionic acid benzenesulfonic acid Hyposulfite contains a single body; amine groups of dimethylamine ethyl acrylate and ethyl pyrrolidone contain a single body; hydroxyethyl (meth) acrylate and hydroxypropyl (meth) acrylate contain a single body Measuring body; (meth) acrylamide, dimethyl (meth) acrylamide, n-butyl (meth) acrylamide, tetramethylbutyl (meth) acrylamide, n-hydroxyl Methyl (meth) acrylamide, ethoxymethyl (meth) acrylamine Amine group contains acrylic series This paper size applies Chinese National Standard (CNS) A4 specification (21〇 × 297 mm) (Please read the precautions on the back before filling this page)-Packing ·

、1T 經濟部智慧財產局員工消費合作社印製 -9 - 552143 Α7 Β7 五、發明説明（7 ) 單量體；（甲基）丙烯酸胺基乙酯、（甲基）丙烯酸二甲 胺乙酯、（甲基）丙烯酸二乙胺乙酯、（甲基）丙酸第 3〜丁酯類之烷基胺基烷基含有丙烯系單量體；（甲基） 丙烯酸甲氧基乙酯、（甲基）丙烯酸乙氧基乙酯、（甲基 )丙烯酸丁氧基乙酯、（甲基）丙烯酸四氫糠基酯、（甲 基）丙烯酸甲氧基乙二醇酯、（甲基）丙烯酸甲氧基二乙 二醇酯、（甲基）丙烯酸甲氧基聚乙二醇酯、（甲基）丙 烯酸甲氧基聚丙二醇酯類之烷氧基（或酯結合於側鏈）含 有單量體；（甲基）丙烯酸二醇氧乙酯、（曱基）丙燦酸 半乳糖基氧乙酯、（甲基）丙烯酸甘露糖基氧乙酯、（甲 基）丙烯酸海藻糖基氧乙酯類之糖鏈含有單量體；正〜（ 甲基）丙醯胺基酸類之乙烯系單量體；丙儲酸之月桂酯、 尿素酯、異氰酸酯類之丙烯系單量體；以及（甲基）丙烯 腈、醋酸乙烯酯、丙酸乙烯酯、乙烯氯化物、乙烯吡咯院 酮、乙烯吡啶、乙烯吡嗪、乙烯哌嗪、乙烯薄荷烯酮、乙 烯嘧啶、乙烯吡咯、乙烯咪唑、乙烯己內醯、乙烯噁唑、 乙烯噻唑、乙烯嗎啉、苯乙烯、α -甲基苯乙烯、及雙（ Ν ’ Ν -二甲胺乙基）蘋果酸鹽等之乙烯系之單量體等等 爲例。此等共聚用單體於丙烯系共聚物中，以含2〜6 〇 重量％，較佳者爲5〜5 0重量％之含有量被共聚之。共 聚用單體含量若不在該範圍時，則無法取得充份之粘著力 及具凝聚力之丙烯系共聚物者。 又，本發明黏著劑組成物所含丙烯系黏著劑儘可能使 混合於其之藥劑不分解，可因應所使用藥劑種類進行各種 本紙張尺度適用中國國家標準（CNS ) Α4規格（21〇Χ 297公釐） (請先閱讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs of the Ministry of Economic Affairs of the People's Republic of China. -9-552143 Α7 Β7 V. Description of the invention (7) Monomers; (amino) (meth) acrylate, dimethylamine (meth) acrylate, (Meth) acrylic acid diethylamine ethyl ester, (meth) propionic acid third to n-butyl alkylamine alkyl groups containing propylene-based monosomes; (meth) methoxyethyl acrylate, (methyl Ethoxyethyl acrylate, butoxyethyl (meth) acrylate, tetrahydrofurfuryl (meth) acrylate, methoxyethylene glycol (meth) acrylate, methyl (meth) acrylate The alkoxy groups (or esters bonded to the side chains) of oxydiethylene glycol, methoxypolyethylene glycol (meth) acrylate, and methacrylate polypropylene glycol (meth) acrylate contain monomer ; Glycoloxyethyl (meth) acrylate, galactosyloxyethylpropionate, mannoyloxyethyl (meth) acrylate, trehalyloxyethyl (meth) acrylate The sugar chain contains a single body; n- (meth) propanyl amino acid-based ethylene single bodies; the month of propanoic acid Esters, urea esters, isocyanates of propylene-based monomers; and (meth) acrylonitrile, vinyl acetate, vinyl propionate, ethylene chloride, vinylpyrrolidone, vinylpyridine, vinylpyrazine, and vinylpiperazine , Vinylmentenone, vinylpyrimidine, vinylpyrrole, ethyleneimidazole, ethylenecaprolactam, ethyleneoxazole, ethylenethiazole, vinylmorpholine, styrene, α-methylstyrene, and bis (Ν′Ν-dimethylformamide Ethyl ethyl) malate and the like are used as examples. These comonomers are copolymerized in a propylene-based copolymer at a content of 2 to 60% by weight, preferably 5 to 50% by weight. When the content of the comonomer is out of this range, a sufficient adhesion and cohesive propylene copolymer cannot be obtained. In addition, the propylene-based adhesive contained in the adhesive composition of the present invention does not decompose the medicine mixed with it as much as possible. Various paper sizes can be applied according to the type of the medicine used. This paper applies the Chinese National Standard (CNS) A4 standard (21〇 × 297). Mm) (Please read the notes on the back before filling out this page)

經濟部智慧財產局員工消費合作社印製 -10 - 552143 ΑΊ ___ Β7 五、發明説明（8 ) 選擇者宜，通常藉由使用具有反應性高之羧基、胺基、及 酸醯胺基等之反應性官能基與之共聚用單體之共聚物使用 後，可減少黏著性組成物，特別是藥劑組成物中丙烯系黏 著劑之配合量，且，藉由標示該反應性官能基後可降低共 聚物之反應性。 本發明黏著劑組成物中，丙烯系黏著劑爲5 0〜9 0 重量％，較佳者爲7 0〜9 0重量％之含量者。 當丙烯系黏著劑含量小於5 0重量％時，則所取得黏 著性組成物凝聚力不足，反之，大於9 0重量％時，則取 得黏著性組成物變得粘稠、貼附膠帶後，感覺不舒服。 本發明黏著劑組成物中，含有多價醇含有之液體成份 者。此多價醇含有液體成份至少含1種之多價醇，其含量 爲總重量黏著劑組成物之1〜3 0重量％者，較佳者爲 7 · 5〜2 ◦重量％者。 含於多價醇之含有液體成份之多價醇係選自甘油、丙 二醇、1，3-丁二醇、二甘油、二丙二醇、1，2，6 -己三醇、山梨糖醇聚乙二醇、以及季戊四醇等者。此等 多價醇於本發明黏著劑組成物中添加脂肪酸金屬鹽做爲凝 聚力改善劑之效果可有效提昇其效果。多價醇之含量爲黏 著劑組成物重量之7 . 5〜5 0重量％者宜。當多價醇之 含量小於7 . 5重量％時，則配合藥劑於所取得之黏著劑 組成物時，此藥劑之經皮吸收性將不足。反之，大於5 0 重量％時，則黏著劑組成物之凝聚力不足，其結果使得膠 帶製劑剝離後，粘著劑層殘留於皮膚。 本紙張尺度適用中國國家標準（CNS〉A4規格（210 X 297公釐） (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 經濟部智慧財產局員工消費合作社印製 -11 - 552143 A7 B7 五、發明説明（9 ) (請先閱讀背面之注意事項再填寫本頁) 該多價醇含有液體成份係加於該多價醇後，選自山梨 聚糖酯化合物，與此山梨聚糖酯化合物相異之脂肪酸酯， 及聚乙烯基吡咯烷酮中至少1種含有者。山梨聚糖酯化合 物，與其不同種之脂肪酸酯及聚乙烯吡咯烷酮有促進多價 醇同時含於黏著劑組成物或藥劑組成物中之藥劑經皮吸收 作用者。 本發明所使用之山梨聚糖酯化合物爲選自具有1 2〜 1 8個碳原子之烴基之脂肪酸，山梨聚糖酯及聚氧亞烷基 山梨糖醇酯者宜。 經濟部智慧財產局員工消費合作社印製 本發明所使用之山梨聚糖酯係選自山梨聚糖單月桂酸 酯、山梨聚糖單棕櫚酸酯、山梨聚糖單硬脂酸酯、山梨聚 糖單油酸酯、山梨聚糖三油酸酯、聚氧乙烯山梨聚糖單月 桂酸酯、聚氧乙烯山梨聚糖單棕櫚酸酯、聚氧乙烯山梨聚 糖單硬脂酸酯、聚氧乙烯山梨聚糖單油酸酯以及聚氧乙烯 山梨聚糖三油酸酯等者。其中又以山梨聚糖單月桂酸酯、 山梨聚糖油酸酯、山梨聚糖三油酸酯、聚氧乙烯山梨聚糖 單月桂酸酯、聚氧乙烯山梨聚糖單棕櫚酸酯、以及聚氧乙 烯山梨聚糖單硬脂酸酯於高透濕下具高藥劑滲透性之經皮 吸收膠帶製劑爲較理想者。 含於多價醇之含有液體成份之山梨聚糖酯化合物之含 量爲總重量黏著劑組成物之0 . 5〜2 0重量％者宜，而 1〜1 0重量％者爲更佳。當山梨聚糖酯含量小於0 . 5 重量％時，則含藥劑於黏著劑組成物時，此藥劑之提昇經 皮吸收性效果不彰，反之，大於2 0重量％時，則所取得 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -12- 經濟部智慧財產局員工消費合作杜印製 552143 A7 ___ _B7 五、發明説明（1〇) 黏著劑組成物之本身凝聚力不足，所取得膠帶、或膠帶製 劑由皮膚剝離時，則部份粘著層殘留於皮膚。 含於多價醇含有液體成份之脂肪酸酯（與山梨聚糖酯 化合物不同種類）係以選自異丙基肉豆蔻酸酯、異丙基棕 櫚酸酯、異辛基棕櫚酸酯、油酸乙酯、以及癸二酸二乙酯 等者爲宜。此等脂肪酸酯中又以異丙基肉豆蔻酸酯及/或 異辛基棕櫚酸酯者宜。此高級脂肪酸酯之含量爲黏著劑組 成物總重量之1〜3 0重量％者宜，較佳者爲5〜2 0重 量％者。當脂肪酸酯含量小於1重量％時，則含於組成物 中之藥劑時，此藥劑無法有效提昇經皮吸收性，反之，大 於3 0重量％時，黏著劑組成物本身凝聚力不足，則部份 粘著劑層由膠帶製劑剝離時殘留於皮膚。 多價醇含有之液體成份爲含有聚乙烯基吡咯烷酮時， 其含量爲組成物總重量之3〜2 0重量％者宜，較佳者爲 5〜1 0重量％者。此含量若大於2 0重量％時，則取得 黏著劑組成物本身凝聚力不足，膠帶、或膠帶製劑剝離時 ，部份黏著層殘留於皮膚。反之，小於3重量％時，配合 藥劑於所組成之黏著劑組成物時，則此藥劑無法有效提昇 經皮吸收性之效果。 本發明所使用之多價醇含有液體成份中，於山梨聚糖 酯藉由倂用與其不同種類之脂肪酸酯及/或聚乙烯基吡咯 烷酮，特別是倂用脂肪酸酯後，可更提昇含於黏著劑組成 物中藥劑之經皮吸收性。此時山梨聚糖酯與其倂用之脂肪 酸酯及/或聚乙烯吡咯烷酮之合計含量爲黏著劑組成物合 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） ~ "13- (請先閲讀背面之注意事項再填寫本頁)Printed by the Employees' Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs -10-552143 ΑΊ ___ Β7 V. Description of the invention (8) The choice is preferred, usually through the use of highly reactive carboxyl, amine, and acid amine groups After using the copolymer of the copolymerizable monomer with the functional group, the amount of the adhesive composition, especially the propylene-based adhesive in the pharmaceutical composition can be reduced, and the copolymerization can be reduced by marking the reactive functional group. Reactivity. In the adhesive composition of the present invention, the content of the propylene-based adhesive is 50 to 90% by weight, preferably 70 to 90% by weight. When the content of the propylene-based adhesive is less than 50% by weight, the cohesive force of the obtained adhesive composition is insufficient. On the other hand, when it is more than 90% by weight, the obtained adhesive composition becomes viscous. Comfortable. The adhesive composition of the present invention contains a liquid component contained in a polyvalent alcohol. This polyvalent alcohol contains at least one kind of polyvalent alcohol with a liquid content of 1 to 30% by weight based on the total weight of the adhesive composition, and more preferably 7.5 to 2% by weight. The liquid component-containing polyvalent alcohol contained in the polyvalent alcohol is selected from the group consisting of glycerin, propylene glycol, 1,3-butanediol, diglycerol, dipropylene glycol, 1,2,6-hexanetriol, and sorbitol polyethylene glycol. Alcohols, and pentaerythritol. The effect of adding such a polyvalent alcohol to the adhesive composition of the present invention as a cohesiveness improver can effectively enhance its effect. The content of the polyvalent alcohol is preferably 7.5 to 50% by weight based on the weight of the adhesive composition. When the content of the polyvalent alcohol is less than 7.5 wt%, when the agent is compounded with the obtained adhesive composition, the percutaneous absorption of the agent will be insufficient. On the other hand, if it is more than 50% by weight, the cohesive force of the adhesive composition is insufficient, and as a result, the adhesive layer remains on the skin after the tape preparation is peeled off. This paper size applies to Chinese national standards (CNS> A4 size (210 X 297 mm) (Please read the precautions on the back before filling out this page) Binding and ordering Printed by the Intellectual Property Bureau Employee Consumer Cooperatives of the Ministry of Economic Affairs -11-552143 A7 B7 V. Description of the invention (9) (Please read the notes on the back before filling this page) The polyvalent alcohol contains a liquid component added to the polyvalent alcohol, and is selected from sorbitan ester compounds, and this sorbitan Fatty acid esters with different ester compounds, and at least one of polyvinylpyrrolidone. Sorbitan ester compounds, and different types of fatty acid esters and polyvinylpyrrolidone can promote polyvalent alcohols to be contained in the adhesive composition at the same time Or a dermal absorption agent in a pharmaceutical composition. The sorbitan ester compound used in the present invention is a fatty acid selected from the group consisting of a hydrocarbon group having 12 to 18 carbon atoms, a sorbitan ester, and a polyoxyalkylene group. Sorbitol esters are preferred. The sorbitan esters used in the present invention printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs are selected from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, and sorbitan. Polysaccharide monostearate, sorbitan monooleate, sorbitan trioleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan Polysaccharide monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan trioleate, etc. Among them, sorbitan monolaurate, sorbitan oleate, Sorbitan trioleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, and polyoxyethylene sorbitan monostearate are highly effective at high moisture permeability Permeable percutaneous absorption tape preparations are preferred. Liquid-containing sorbitan ester compounds contained in polyvalent alcohols are preferably 0.5 to 20% by weight of the total adhesive composition, and 1 to 10% by weight is more preferred. When the sorbitan ester content is less than 0.5% by weight, when the agent is contained in an adhesive composition, the effect of improving the percutaneous absorption of the agent is not good, otherwise, it is greater than At 20% by weight, the paper size obtained is subject to Chinese national standards ( CNS) A4 specification (210X297 mm) -12- Consumption cooperation by employees of the Intellectual Property Bureau of the Ministry of Economic Affairs 552143 A7 ___ _B7 V. Description of the invention (1) The adhesive composition itself has insufficient cohesion, and the obtained tape, or tape When the preparation is peeled from the skin, a part of the adhesive layer remains on the skin. The fatty acid ester (different from the sorbitan ester compound) contained in the polyvalent alcohol and containing a liquid component is selected from isopropyl myristate, Isopropyl palmitate, isooctyl palmitate, ethyl oleate, and diethyl sebacate are preferred. Among these fatty acid esters, isopropyl myristate and / or isopropyl Octyl palmitate is preferred. The content of this higher fatty acid ester is 1 to 30% by weight of the total weight of the adhesive composition, and more preferably 5 to 20% by weight. When the content of fatty acid ester is less than 1% by weight, when the agent is contained in the composition, the agent cannot effectively improve transdermal absorption. On the other hand, when the content of the fatty acid ester is more than 30% by weight, the cohesion of the adhesive composition itself is insufficient. The part of the adhesive layer remains on the skin when peeled from the tape preparation. When the liquid component contained in the polyvalent alcohol is polyvinylpyrrolidone, its content is preferably 3 to 20% by weight based on the total weight of the composition, and more preferably 5 to 10% by weight. When the content is more than 20% by weight, the cohesive force of the adhesive composition itself is insufficient, and when the tape or the tape preparation is peeled off, part of the adhesive layer remains on the skin. On the other hand, when it is less than 3% by weight, when the pharmaceutical composition is compounded with the adhesive composition, the pharmaceutical cannot effectively improve the percutaneous absorption effect. The polyvalent alcohol used in the present invention contains liquid ingredients. By using different types of fatty acid esters and / or polyvinylpyrrolidone in sorbitan esters, especially using fatty acid esters, the content can be further increased. Transdermal absorption of the agent in the adhesive composition. At this time, the total content of sorbitan esters and their fatty acid esters and / or polyvinylpyrrolidone is the adhesive composition. The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) ~ " 13- (Please read the notes on the back before filling this page)

552143 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明説明（11 ) 計量之10〜40重量％者宜。 本發明黏著劑組成物係含有具有8〜1 8個碳原子烴 基之脂肪酸與1〜3價之金屬所組成之脂肪酸金屬鹽者。 此脂肪酸金屬鹽爲具有提高黏著劑組成物之凝聚力效果者 ，較佳者爲C 8〜C : 8脂肪酸，如選自：辛酸、月桂酸、 肉豆蔻酸、硬脂酸及油酸之脂肪酸與鹹金屬（如：鈉）’ 鹹土類金屬（如··鎂）、鋅、及鋁之金屬鹽者。 本發明所使用之脂肪酸金屬鹽係選自：辛酸鈉、月桂 酸鈉、肉豆蔻酸鈉、硬脂酸鈉、油酸鈉、硬脂酸鎂、硬脂 酸鋅、以及硬脂酸鋁等。又，此脂肪酸金屬鹽藉由與該多 價醇倂用後，可更提昇黏著劑組成物之凝聚力。脂肪酸金 屬鹽之配合量爲黏著性組成物總重量之0 . 0 1〜1 〇重 量％者宜，更佳者爲0·1〜5重量％者。脂肪酸金屬鹽 之含量小於0 · 1重量％時，則取得黏著劑組成物之凝聚 力不足，又，大於1 0重量％時，則於取得黏著劑組成物 中產生過度凝膠化造成困擾。又，脂肪酸金屬鹽配合藥劑 於黏著劑組成物時，亦將影響其經皮吸收性。 本發明透濕性膠帶係使含該本發明黏著劑組成物之米占 著層形成於支撑體之一表面上者。 做爲本發明透濕性膠帶所使用之支撑體者以具有M _ 性及透濕性者宜，惟，對於化學藥劑，特別是醫藥上，以 不可移行（滲透、擴散等）者爲宜。做爲具有防止此醫_ 移行之特性之支撑體者可使用由聚乙烯系、聚丙丨希/系\ _ 酯系、聚醯胺系、聚四氟乙烯系、聚氯化乙烯系、或聚月安 1紙張尺度適用中國國家標準（〇阳）八4規格（210/297公釐） · --------- -14 - (請先閲讀背面之注意事項再填寫本頁) -裝·552143 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (11) It is suitable to measure 10 ~ 40% by weight. The adhesive composition of the present invention is a fatty acid metal salt composed of a fatty acid having a hydrocarbon group of 8 to 18 carbon atoms and a metal of 1 to 3 valence. The fatty acid metal salt has the effect of improving the cohesiveness of the adhesive composition, and is preferably a C 8 ~ C: 8 fatty acid, such as a fatty acid selected from the group consisting of caprylic acid, lauric acid, myristic acid, stearic acid, and oleic acid. Salt metal (such as: sodium) 'Salt metal (such as magnesium), zinc, and aluminum metal salts. The fatty acid metal salt used in the present invention is selected from the group consisting of sodium caprylate, sodium laurate, sodium myristate, sodium stearate, sodium oleate, magnesium stearate, zinc stearate, and aluminum stearate. In addition, the fatty acid metal salt can further improve the cohesiveness of the adhesive composition after being used with the polyvalent alcohol. The compounding amount of the fatty acid metal salt is preferably from 0.01 to 10% by weight based on the total weight of the adhesive composition, and more preferably from 0.1 to 5% by weight. When the content of the fatty acid metal salt is less than 0.1% by weight, the cohesive force of the adhesive composition obtained is insufficient, and when it is more than 10% by weight, excessive gelation occurs in the obtained adhesive composition, which causes trouble. In addition, when a fatty acid metal salt is compounded with an adhesive composition, it also affects its percutaneous absorption. The moisture-permeable tape of the present invention is one in which a rice-containing layer containing the adhesive composition of the present invention is formed on one surface of a support. As the support used for the moisture-permeable tape of the present invention, those having M _ and moisture permeability are suitable, but for chemical agents, especially in medicine, it is preferable to be immovable (permeation, diffusion, etc.). As a supporter with the characteristics of preventing this medical _ migration, polyethylene-based, polypropylene-based Greek / system \ _ ester-based, polyamide-based, polytetrafluoroethylene-based, polyvinyl chloride-based, or polymer Yuean 1 paper size applies Chinese National Standard (Oyang) 8 4 specifications (210/297 mm) · --------- -14-(Please read the precautions on the back before filling this page)- Loading ·

、1T 552143 A 7 B7 五、發明説明（12 ) 酯系聚合物所組成之塑料薄膜，以及多孔質薄膜，及此等 聚合物所形成之纖維使用後所形成之不織布，編織物者。 該多孔質薄膜、不織布、編織物具有良好之透氣性、透濕 性及柔軟性者，可有效防止刺激皮膚之支撑體者。 本發明膠帶以具有3 0 0 g /m 2 ·日以上之透濕度 者宜，更理想者爲600〜800g/m2·日者。 又，本發明膠帶之粘著層以具有5〜1 0 0 〇 /zm之 厚度者宜，更佳者爲1 0〜5 0 0//ni者。 本發明膠帶可藉由熱融塗工法、乳劑塗工法或溶劑塗 工法於支撑體之一表面上形成含本發明黏著劑組成物之黏 著層後製造之。該塗工法中又以溶劑塗工法者爲較佳。此 溶劑塗工法中，黏著劑組成物溶於低沸點溶劑（較佳者爲 具有8 0 °C以下之沸點者），如··醋酸乙酯後，調製塗工 用d ο p，將此d ο p塗於支撑體表面後，乾燥後形成黏 著層或將該d ο p塗於脫模材料之一表面後，乾燥此塗佈 層後，將脫模材上之塗佈黏著層接合於支撑體上。 做爲調製該d ο p所使用之溶媒者如：醋酸乙酯、氯 仿、氯化亞甲基、環己烷、四氫呋喃等例。其中又以醋酸 乙酯者爲較佳。又，醋酸乙酯與醇之混合溶媒可防止脂肪 酸金屬鹽添加後之凝膠化爲較佳者。 又，做爲脫模材料者，如：於表面塗抹聚矽氧、氟等 之剝離劑之金屬箔、聚酯、聚烯烴、纖維酯、聚醯胺等塑 料薄膜者。此脫模材料亦可使用於黏著膠帶之黏著層表面 至使用時之保護者。 本紙張尺度適用中國國家標準（CNS ) A4規格（2]0X297公釐） 裝-- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局工消費合作社印製 -15- 552143 A7 ______B7 五、發明説明（13) (請先閲讀背面之注意事項再填寫本頁) 本發明黏著性藥劑組成物係含本發明該黏著劑組成物 與爲此黏著劑組成物重量之0 · 0 5〜4 0重量％，較佳 者爲5〜1 0重量％之藥劑含有者。藥劑含量小於 〇 · 0 5重量％時，則取得藥劑組成物無法發揮添加劑所 期待之效果。反之，藥劑含量大於4 0重量％則所取得黏 著劑組成物之黏著性不足。 本發明黏著性藥劑組成物所使用之藥劑包括非固醇類 消炎鎭痛劑、抗高血壓劑、局部麻醉劑、抗生物質、鈣拮 抗劑、強心劑、抗癲癎劑、降壓利尿劑、抗真菌劑、抗過 敏、抗組織胺劑、抗惡性腫瘤劑、抗精神病劑、抗暈玄劑 、睡眠調整劑、冠血管擴張劑、激素劑、降血壓劑、氣喘 、鼻炎治療劑、降血糖劑、以及抗潰瘍劑等藥理活化物質 之1種以上者。 下記表示各藥劑之代表例。 1 )非固醇類消炎鎭痛劑：乙醯水楊酸、水楊酸甲酯、 Indomethacin、diclofenack、Ibuprofen、可多普落菲 、flurbiprofen、m e f e n a m i c a c i d、phenylbutazone、 經濟部智慧財產局員工消費合作社印製 A m i η o p y l. i n、p i r o x i c a m、以及 f e 1 v i n a c k 等 2)抗高血壓劑^113〇1〇1、八(161*〇11〇1、？1.〇?&11〇1〇1、1：^(1〇1，〇1 、A j m a 1 i n e、A1 p r e η o 1 o 1 H C1、m e t ο p ι· o 1 ο 11 a l* t r a t e、 Quinidine Sulfate , Timolol maleate、及 Disopyramide 等 3 )局部麻醉劑：T e 11· a c a i n e、P ι· o c a i η e、B e η z o c a i n e、以 及 Lidocaine 等 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -16- 經濟部智慧財產局R工消費合作社印製 552143 A7 B7 五、發明説明（14) 4 )抗生素：Chloramphenicol、以及 tetracycline 等 5 )齡诘抗劑：nifidipine 、及 nicardipine 等 6 )強心劑：Dopamine HC1 、及 Digitalis 等 7 )抗癲搞劑：Valproate sodium 、及 phenytoin 等 8 )降壓利尿劑：h y d ι· 〇 c li 1 〇 r t h i a z i d e 等 9 )抗真菌劑·· Griseofulvin 、及 Amphotericin B 等 1 0 )抗過敏·組織胺劑·· Cycloheptadin HC1、 d i p h e n h y d r a m i η H C1、m e k i t a d i n 及 p h e n b e n z a m i n 等1T 552143 A 7 B7 V. Description of the invention (12) Plastic films composed of ester polymers, porous films, and non-woven fabrics and knitted fabrics formed by using fibers formed from these polymers. Those porous films, non-woven fabrics, and knitted fabrics having good air permeability, moisture permeability, and softness can effectively prevent skin supporters from being irritated. The adhesive tape of the present invention preferably has a moisture permeability of 300 g / m 2 · day or more, and more preferably 600 to 800 g / m 2 · day. In addition, the adhesive layer of the tape of the present invention preferably has a thickness of 5 to 100 / zm, and more preferably 10 to 500 / ni. The adhesive tape of the present invention can be manufactured by forming an adhesive layer containing the adhesive composition of the present invention on one surface of a support by a hot melt coating method, an emulsion coating method, or a solvent coating method. In this coating method, a solvent coating method is more preferable. In this solvent coating method, the adhesive composition is dissolved in a low boiling point solvent (preferably one having a boiling point below 80 ° C), such as ethyl acetate, and then d ο p is prepared for coating. ο p is coated on the surface of the support, and then dried to form an adhesive layer or d ο p is coated on one of the surfaces of the release material, and after drying this coating layer, the coated adhesive layer on the release material is bonded to the support Physically. Examples of the solvent used for the preparation of d p include ethyl acetate, chloroform, methylene chloride, cyclohexane, and tetrahydrofuran. Among them, ethyl acetate is preferred. In addition, a mixed solvent of ethyl acetate and alcohol can prevent gelation of fatty acid metal salt after addition. In addition, as a mold release material, for example, a metal foil, polyester, polyolefin, fiber ester, or polyamide film coated with a release agent such as silicone or fluorine is applied to the surface. This release material can also be used on the surface of the adhesive layer of the adhesive tape to the protector during use. This paper size applies to Chinese National Standard (CNS) A4 specification (2) 0X297 mm. Packing-(Please read the notes on the back before filling this page) Order printed by the Ministry of Economic Affairs Intellectual Property Bureau Industrial Consumer Cooperatives -15- 552143 A7 ______B7 V. Description of the invention (13) (Please read the notes on the back before filling out this page) The adhesive pharmaceutical composition of the present invention contains the adhesive composition of the present invention and the weight of the adhesive composition of 0 · 0 5 to 40% by weight, preferably 5 to 10% by weight of a pharmaceutical agent. When the content of the drug is less than 0.05% by weight, the effect obtained by the additive cannot be exhibited by the pharmaceutical composition. On the contrary, if the content of the agent is more than 40% by weight, the adhesiveness of the obtained adhesive composition is insufficient. The medicament used in the adhesive pharmaceutical composition of the present invention includes non-steroidal anti-inflammatory and analgesic agents, antihypertensive agents, local anesthetics, anti-biomass, calcium antagonists, cardiotonic agents, antiepileptics, antihypertensive diuretics, and antifungals. Agents, anti-allergic, anti-histamine, anti-malignant agents, antipsychotics, anti-halogen agents, sleep modifiers, coronary vasodilators, hormones, antihypertensive agents, asthma, rhinitis treatment agents, hypoglycemic agents, And one or more pharmacologically active substances such as antiulcer agents. The following shows representative examples of each medicine. 1) Non-steroidal anti-inflammatory painkillers: Acetylsalicylic acid, methyl salicylate, Indomethacin, diclofenack, Ibuprofen, Codoprofil, flurbiprofen, mefenamicacid, phenylbutazone, printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A mi η opy l.in, piroxicam, and fe 1 vinack, etc. 2) Antihypertensive agents ^ 113〇101, eight (161 * 〇11〇1,? 1.〇? &Amp; 1101) , 1: ^ (101, 〇1, A jma 1 ine, A1 pre η o 1 o 1 H C1, met ο p · o 1 ο 11 al * trate, Quinidine Sulfate, Timolol maleate, and Disopyramide, etc. 3 ) Local anesthetics: T e 11 · acaine, P · · ocai η e, Be η zocaine, and Lidocaine, etc. The paper standards are applicable to the Chinese National Standard (CNS) A4 specification (210X 297 mm) -16- Intellectual Property of the Ministry of Economic Affairs Printed by the Bureau of Industrial and Consumer Cooperatives 552143 A7 B7 V. Description of the invention (14) 4) Antibiotics: Chloramphenicol, and tetracycline, etc. 5) Age-defying agents: nifidipine, and nicardipine, etc. 6) Cardiotonics: Dopamine HC1, and Digitalis 7) Anti-epileptic agents: Valproate sodium, and phenytoin, etc. 8) Antihypertensive diuretics: hyd. 〇c li 1 〇rthiazide, etc. 9) Antifungal agents · Griseofulvin, and Amphotericin B, etc. 1) Antiallergic · Histamines Cycloheptadin HC1, diphenhydrami η H C1, mekitadin, phenbenzamin, etc.

1 1 )抗惡性腫瘤劑·· 5 — fluorouracil 、及 mitomycin C 等 1 2 )抗精神病劑：E t i z ο 1 a m 、m a p r o t i 1 i n e H C1、1 1) Anti-malignant agents ·· 5-fluorouracil, mitomycin C, etc. 1 2) Antipsychotics: E t i z ο 1 a m, ma p r o t i 1 i n e H C1,

Amitriptyline HCI、mianserin HC1、及 Diaze pam 等 1 3 )抗暈眩劑·· Scopolamine 等 1 4 )睡眠調整劑：Amobarbital 及 phenbarbital 等 1 5 )冠血管擴張劑：dipyridamol、diltiazem、Isosorbide d i n i t r a t e、h i f e d i p i n e、nitroglycerin、及 p e t a e r y t h r i o 1 t e t r a n i t r a t e 等 1 6 )激素劑：雌激素、e s t r o g e n、t e s t o s t e r ο n e、 progesterone 、及 prostaglandine 等 1 7 )降壓齊丨J : C r ο n i d i η H C1、p r a z o c i η H C1、g u a p h a c i n HC1、 bunazocin HC1、 Arothinol HC1 、 bunitro 1 o 1 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） (請先閲讀背面之注意事項再填寫本頁)Amitriptyline HCI, mianserin HC1, and Diaze pam, etc. 1 3) Anti-dizziness agents Scopolamine, etc. 1 4) Sleep modifiers: Amobarbital and phenbarbital, etc. 1 5) Coronary vasodilators: dipyridamol, diltiazem, Isosorbide dinitrate, hifedipine, nitroglycerin , And petaerythrio 1 tetranitrate, etc. 16) Hormone agents: estrogen, estrogen, testoster ο ne, progesterone, and prostaglandine, etc. 7) Blood pressure reduction 丨 J: C r ο nidi η H C1, prazoci η H C1, guaphacin HC1 , Bunazocin HC1, Arothinol HC1, bunitro 1 o 1 This paper size applies to China National Standard (CNS) A4 specification (210X 297 mm) (Please read the precautions on the back before filling this page)

-17- 552143 經濟部智慧財產局員工消費合作社印製 Μ Β7五、發明説明（15 ) HC1、penbutolol sulfate、guanabenzacetate.及 e n a r a p r i 1 m a 1 e a t e 等 1 8 )氣喘、鼻炎治療劑：Azerastin HC1、Chlomoglic acid 、及 Ketothiphen fumalate 等 1 9 )降血糖劑：Grichlazid、Gribenlamide 等 2 0 )抗潰瘍劑：溴化 g 1 ic〇piι·οnium、fam〇thide 、及 chlebobride malicacid 等 上述藥劑因應治療目的、作用等可倂用2種以上者。 本發明黏著性藥劑組成物中，於該丙烯系黏著劑中藉 由同時配合該多價醇含有液體成份與脂肪酸金屬鹽後、藥 劑經皮吸收性不會下降，可提昇組成物之凝聚力。 本發明膠帶製劑係使含本發明黏著性藥劑組成物之黏 著藥劑層形成於支撑體之一表面後被製造者。 本發明膠帶製劑之支撑體可選自與該本發明透濕性膠 帶支撑體相同材料者。又，黏著藥劑層係由該本發明黏著 性藥劑組成物與該透濕性膠帶製造中之黏著層形成方法同 法進行後可形成者。 本發明膠帶製劑中，其透濕度爲3 〇 〇 g /m 2 ·日 以上者宜，更佳者爲6〇〇〜800g/m2.日者。 又’本發明膠帶製劑中其粘著藥劑層之厚度爲5〜 1 0 0 0 // m者宜、1〇〜5 0 0 // m者更佳。本發明膠 帶製劑中於其粘著藥劑層中同時含有藥劑與本發明黏著劑 組成物者’因此，此黏著藥劑層可顯示良好之藥劑經皮吸 (請先閲讀背面之注意事項再填寫本頁) 裝· 、-口 線 本紙張尺度適用中國國家標準（CNS ) A4規格（21〇χ297公慶） -18- 552143 A7 B7 五、發明説明（16 ) 收性，且顯示良好之透濕性及透濕性者。 實施例 藉由下記實施例進行本發明更詳細說明。實施例中膠 帶製劑之藥劑經皮吸收性試驗、黏著層或黏著藥劑層之凝 聚力試驗、以及剝離試驗、及透濕度測定試驗藉由下記方 法進行之。 C 1 )藥劑經皮吸收性試驗 於垂直型擴散 Cell上部將皮膚外用藥劑組成物（ 〇· 4cm2x 〇 . 4cm2)裝置於黏著YMP ( Yucatan Micro Pig :雌 2 0 k g )之背部皮膚後，於 cell 下部置入1 〇 m 1之磷酸緩衝溶液（p Η = 7 · 4、雌激 素時含1 %之〇1〇(^(：丨13111〖316仏）、攪拌2 4小時（雌 激素時爲4 8小時）。攪拌後，由 Cell下部使磷酸緩衝 溶液做成樣本、使移行於cell下部之磷酸緩衝溶液之藥 劑濃度藉由液體色譜法進行定量。 (2 )凝聚力試驗 將含有供試黏著劑組成物或黏著性藥劑組成物之膠帶 或膠帶製劑之黏著層或黏著藥劑層黏著於膠木板後，將此 剝離’藉由目視進行判定膠木板面上之黏著層或黏著藥劑 層殘留之有無。 良好：無附著黏著層或黏著藥劑層之殘留 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） (請先閲讀背面之注意事項再填寫本頁) 裝. 經濟部智慧財產局員工消費合作社印製 -19- 552143 A7 _______B7 五、發明説明（17) (請先閲讀背面之注意事項再填寫本頁) 不良：殘留附著黏著層或黏著藥劑層 (3 )剝離試驗 將寬1 2 m m之供試膠帶之黏著層或膠帶製劑之黏著 藥劑層黏著於膠木板後，密合兩者面積1 c m 2載重 3 0 0 g者。再使供試膠帶或膠帶製劑之一端成1 8 〇度 之剝離角度，於3 0 〇 m m /分之剝離速度下進行剝離， 之後，測定其剝離強度。 (4 )透濕度試驗 於內徑3 8 m m之玻璃秤量瓶中置入2 6 g之氯化鈣 ，使密合透濕度1 1 0 0 0 g / m 2 ·日之紗布上之黏著 層、黏著藥劑層或支撑體固定於秤量瓶上部。將此置於溫 度4 0 t，相對溫度7 0 %之恒溫恒濕槽內放置3小時， 由供試評量瓶內容物之質量增加量算出滲入1平方公尺面 積2 4小時供試體之水份量，以取得之測定値顯示黏著層 、黏著藥劑層或支撑體之透濕度。 經濟部智慧財產局員工消費合作社印製 實施例所使用之材料如下。 (1 )本實施例所使用之可多普落菲、felvinack係 由S i g m a c h e m i c a 1公司所取得者雌激素、雄激素係由 Tokyo Kasei Organic Chemical 公司所取得者。甘油（ GC)、 1 ，2，6 -己三醇、異丙基肉豆蔻酸酯（ I P Μ )、異辛基棕櫚酸酯（I〇P )、油酸乙酯（ 〇Ε )、硬脂酸鎂（S + M g )、山梨聚糖單月桂酸酯（ 本紙張尺度適用中國國家標準（CNS ) A4規格（2丨〇><297公釐） -20- 552143 A7 B7 五、發明説明（18) SPAN20)、山梨聚糖單油酸酯（SPAN80)、 (請先閲讀背面之注意事項再填寫本頁} 山梨聚糖三油酸酯（Tween 20)、聚氧乙烯山梨聚糖 單棕櫚锻酯（丁 w e e η 4 0 )、聚氧乙烯山梨聚糖單硬脂 酸酯（Tween 6 0 )、及聚乙烯吡咯烷酮（ρ ν ρ )均 由 Kanto Chemical公司購入者。 (2 )渗透貫驗所使用之豬皮係由 Charles River公 司所取得者。 (3 )做爲支撑基材者係使用由聚對苯二甲酸乙酯所 形成之具透濕性之織布者。 (4 )做爲參考樣品者係使用 morastep (久光製藥 )、celltach (武田藥品工業）者。morastep係含可多 普落菲之藥劑者，具有橡膠系黏著劑所使用之黏著層者， 無透濕性之膠帶製劑者。又，celltach係含有 phelbinack藥劑之糊劑者。 經濟部智慧財產局g(工消費合作社印製 針對下記實施例1 ，2中使用2種多價醇後其凝聚力 進行討論。比較例1〜6中選自脂肪酸金屬鹽或無多價醇 系者。另外，參考例1係使用 morastep後，進行比較討 論者。 實施例1 於9 . 3 g之丙烯系黏著劑（使用甲基丙烯酸甲酯7 wt%、 2 —乙基己基丙烯酸酯9〇wt%、丙烯酸3 w t %經共聚後取得之丙烯系黏著劑：溶於醋酸乙酯之 21 _ 6%dop狀者。）中添加2 · 0g甘油、 •—-— 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -21 - 552143 A7 __B7_ 五、發明説明（19 ) 〇_ 0 4 g之硬脂酸鎂後，再加入4 5 m 1之醋酸乙酉旨. 乙醇混合液（醋酸乙酯：乙醇=2 ·· 1 ( v / v )後於勺 漿器攪拌後進行調製黏著層用塗佈液。此塗佈液以聚？夕_ 進行處理後之P E T薄膜上以乾燥後厚度爲5 0 // m之刮 刀進行塗佈之。將此塗佈液層於6 0 °C下進行乾燥3 〇分 鐘後形成厚度5 0 // m之黏著層。取得膠帶用於凝聚力試 驗及剝落力試驗。此膠帶之黏著層爲含4 9重量％之丙烯 系黏著劑、50重量％之甘油及1重量％之硬脂酸鎂者。 試驗結果如表1所示。 實施例2 與實施例1同法製造膠帶。惟，以1 ，2，6 -己三 醇取代甘油。 試驗結果如表1所示。 比較例1 與實施例1同法製造膠帶。惟，使黏著劑組成物（塗 佈液）所取得乾燥後之黏著層調製成丙烯系黏著劑5 〇重 量％及甘油5 0重量％之組成者。 比較例2 與貫施例1同法製造膠帶。惟，使黏著劑組成物（塗 佈液）所取得乾燥後之黏著層調製成丙烯系黏著劑 4 9 · 9 5重里％、甘油5 0重量％及硬脂酸鎂〇 ·◦ 5 i紙張尺度適用中國國家標準（ CNS ) A4規格（210X297公17----— -22- f請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產苟員工消費合作社印製-17- 552143 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs Β7. V. Invention Description (15) HC1, penbutolol sulfate, guanabenzacetate. And enarapri 1 ma 1 eate, etc. 1 8) Asthma, rhinitis treatment agent: Azerastin HC1, Chlomoglic acid, and Ketothiphen fumalate, etc. 19) Hypoglycemic agents: Grichlazid, Grribenamide, etc. 20) Antiulcer agents: bromide g 1 ic〇piι · οnium, fam〇thide, and chlebobride malicacid, etc. according to the purpose of treatment, role, etc. Two or more can be used. In the adhesive pharmaceutical composition of the present invention, after the polyvalent alcohol contains a liquid component and a fatty acid metal salt in the propylene-based adhesive at the same time, the percutaneous absorption of the pharmaceutical does not decrease, and the cohesion of the composition can be improved. The tape preparation of the present invention is made by forming an adhesive agent layer containing the adhesive agent composition of the present invention on one surface of a support. The support of the tape preparation of the present invention can be selected from the same material as the moisture-permeable adhesive tape support of the present invention. In addition, the adhesive agent layer can be formed after the adhesive agent composition of the present invention and the method for forming an adhesive layer in the manufacture of the moisture-permeable tape are carried out in the same manner. In the tape preparation of the present invention, the moisture permeability is preferably 300 g / m 2 · day or more, and more preferably 600 to 800 g / m 2 .day. Also, the thickness of the adhesive agent layer in the tape preparation of the present invention is preferably 5 to 1 0 0 0 // m, and more preferably 10 to 5 0 0 // m. The adhesive tape preparation of the present invention contains both the pharmaceutical agent and the adhesive composition of the present invention in its adhesive agent layer. Therefore, this adhesive agent layer can show good drug percutaneous absorption (please read the precautions on the back before filling this page ) The size of this paper is applicable to the Chinese National Standard (CNS) A4 specification (21〇297297) -18- 552143 A7 B7 V. Description of the invention (16) It is collectable and shows good moisture permeability and Permeable. Examples The present invention will be described in more detail by the following examples. The percutaneous absorption test of the tape preparation in the examples, the cohesiveness test of the adhesive layer or the adhesive agent layer, the peeling test, and the moisture permeability measurement test were performed by the following methods. C 1) Percutaneous absorption test of the medicament On the upper part of the vertical diffusion cell, a skin external medicament composition (0.4 cm2 x 0.4 cm2) was mounted on the back skin of YMP (Yucatan Micro Pig: female 20 kg), and then placed in a cell Put a phosphate buffer solution of 10 mM in the lower part (p 4 = 7 · 4, estrogen containing 1% 〇10 (^ (: 131131 〖316 仏), stir for 2 4 hours (4 for estrogen) 8 hours). After stirring, the phosphate buffer solution is made into a sample from the lower part of the cell, and the concentration of the phosphate buffer solution in the lower part of the cell is quantified by liquid chromatography. (2) Cohesion test will contain the test adhesive composition After the adhesive layer or adhesive agent layer or adhesive agent layer of the adhesive agent composition or adhesive agent agent is adhered to the bakelite board, this peeling is performed by visual inspection to determine whether the adhesive layer or the adhesive agent layer remains on the bakelite board. Good ： No residue of adhesive layer or adhesive agent layer. The paper size is applicable to Chinese National Standard (CNS) A4 specification (210X 297 mm) (Please read the precautions on the back before filling this page). Printed by the Bureau ’s Consumer Cooperatives-19- 552143 A7 _______B7 V. Description of the invention (17) (Please read the precautions on the back before filling in this page) Defect: Residual adhesion of the adhesive layer or adhesive agent layer (3) Peel test will be wide 1 The adhesive layer of the 2 mm test tape or the adhesive agent layer of the tape preparation is adhered to the bakelite board, and the area of the two is 1 cm 2 and the load is 3 0 0 g. Then one end of the test tape or the tape preparation is 1 8 The peeling angle is 0 °, and the peeling strength is measured at a peeling speed of 300 mm / min, and then the peeling strength is measured. (4) Water permeability test A glass weighing bottle with an inner diameter of 38 mm is placed in a glass measuring bottle of 2 6 g. Calcium chloride is used to make the moisture permeability 1 1 0 0 0 g / m 2 · The adhesive layer, adhesive agent layer or support on the gauze of Rizhi is fixed on the upper part of the measuring bottle. This is placed at a temperature of 40 t, relative temperature Place in a 70% constant temperature and humidity tank for 3 hours, and calculate the amount of water infiltrated into the 1 square meter area for 24 hours from the mass increase of the contents of the bottle for the test. The obtained measurement shows the adhesion layer. , Moisture permeability of adhesive agent layer or support. The materials used in the printed example of the employee's consumer cooperative of the property bureau are as follows: (1) The docopherol and felvinack used in this example are obtained from Sigmachemica 1 and the estrogen and androgen are obtained from Tokyo Kasei Organic. Acquired by Chemical Company. Glycerol (GC), 1,2,6-hexanetriol, isopropyl myristate (IPM), isooctyl palmitate (IOP), ethyl oleate ( 〇Ε), magnesium stearate (S + M g), sorbitan monolaurate (this paper size applies the Chinese National Standard (CNS) A4 specification (2 丨 〇 > < 297 mm) -20- 552143 A7 B7 V. Description of the invention (18) SPAN20), sorbitan monooleate (SPAN80), (please read the notes on the back before filling this page) sorbitan trioleate (Tween 20), poly Oxyethylene sorbitan monopalmitate (butyl wee η 40), polyoxyethylene sorbitan monostearate (Tween 60), and polyvinylpyrrolidone (ρ ν ρ) were purchased by Kanto Chemical Company. . (2) The pigskin used in the penetration test was obtained by Charles River. (3) As the supporting substrate, a moisture-permeable fabric made of polyethylene terephthalate is used. (4) The reference samples are those using morastep (Jiuguang Pharmaceutical) and celltach (Takeda Pharmaceutical Industry). Morastep is a drug containing codoprolide, a person with an adhesive layer for a rubber-based adhesive, and a person who does not have a moisture-permeable tape preparation. Celltach is a paste containing a phelbinack drug. The Intellectual Property Bureau of the Ministry of Economic Affairs (printed by the Industrial and Consumer Cooperatives) discusses the cohesion after using two types of polyvalent alcohols in Examples 1 and 2 below. Comparative examples 1 to 6 are selected from fatty acid metal salts or non-polyvalent alcohols In addition, the reference example 1 was compared and discussed after using morastep. Example 1 9.3 g of propylene-based adhesive (using 7% by weight of methyl methacrylate, 90% by weight of 2-ethylhexyl acrylate) %, Acrylic acid 3 wt% propylene-based adhesive obtained after copolymerization: those dissolved in ethyl acetate 21 _ 6% dop-like.) Add 2 · 0g glycerin, • — — — This paper size applies Chinese national standards ( CNS) A4 specification (210X 297 mm) -21-552143 A7 __B7_ V. Description of the invention (19) 〇_ 0 4 g of magnesium stearate, and then add 4 5 m 1 of ethyl acetate. Ethanol mixed solution ( Ethyl acetate: Ethanol = 2 ·· 1 (v / v), and then stir in a spoon to prepare a coating solution for the adhesive layer. This coating solution is polymerized on a PET film after treatment and dried. Coating with a doctor blade with a thickness of 5 0 // m. This coating liquid layer was dried at 60 ° C for 3 〇 An adhesive layer with a thickness of 50m / m was formed after the bell. The adhesive tape was obtained for the cohesiveness test and the peeling force test. The adhesive layer of this tape was 49% by weight of an acrylic adhesive, 50% by weight of glycerin, and 1% by weight. The test results are shown in Table 1. Example 2 An adhesive tape was produced in the same manner as in Example 1. However, 1,2,6-hexanotriol was used instead of glycerol. The test results are shown in Table 1. Comparative Example 1 An adhesive tape was produced in the same manner as in Example 1. However, the adhesive layer after the adhesive composition (coating liquid) was dried was prepared to have a composition of 50% by weight of an acrylic adhesive and 50% by weight of glycerin. Comparative Example 2 An adhesive tape was produced in the same manner as in Example 1. However, the dried adhesive layer obtained from the adhesive composition (coating liquid) was prepared as a propylene-based adhesive 4 9 · 9 5% by weight and glycerin 5 0. Weight% and magnesium stearate 0 · ◦ 5 i Paper size applies Chinese National Standard (CNS) A4 specification (210X297 male 17 ----— -22- f Please read the notes on the back before filling this page) Ministry of Economy Printed by Intellectual Property Cooperative Employee Cooperative

552143 A7 ____j7 五、發明説明（2〇 ) 霆量％之組成者。 §式驗結果如表1所示。 比較例3 與實施例1同法進行製造膠帶。惟，使黏著劑組成物 (塗佈液）取得之黏著層調製成丙烯系黏著劑4 5重量％ 、甘油5 0重量％及硬脂酸鎂5重量％之組成者。 試驗結果如表1所示。 比較例4 與實施例1同法進行製造膠帶。惟，使黏著劑組成物 (塗佈液）取得之黏著層調製成丙烯系黏著劑4 9重量％ 、異丙基肉豆蔻酸酯5 0重量％及硬脂酸鎂1重量％之組 成者。 試驗結果如表1所示。 比較例5 與比較例4同法進行製造膠帶。惟，以異辛基棕櫚酸 酷取代異丙基肉豆蔻酸酯。 試驗結果如表1所示。 比較例6 與比較例4同法進行製造膠帶。惟，以油酸取代異丙 基肉豆蔻酸酯。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） (請先閲讀背面之注意事項再填寫本頁)552143 A7 ____j7 V. Description of the invention (20) The constituents of %%. § The test results are shown in Table 1. Comparative Example 3 An adhesive tape was produced in the same manner as in Example 1. However, the adhesive layer obtained by the adhesive composition (coating liquid) was prepared as a composition consisting of 45 wt% of propylene-based adhesive, 50 wt% of glycerol, and 5 wt% of magnesium stearate. The test results are shown in Table 1. Comparative Example 4 An adhesive tape was produced in the same manner as in Example 1. However, the adhesive layer obtained by the adhesive composition (coating liquid) was prepared by a combination of 49% by weight of an propylene-based adhesive, 50% by weight of isopropyl myristate, and 1% by weight of magnesium stearate. The test results are shown in Table 1. Comparative Example 5 An adhesive tape was produced in the same manner as in Comparative Example 4. However, iso-octyl palmitate is used instead of isopropyl myristate. The test results are shown in Table 1. Comparative Example 6 An adhesive tape was produced in the same manner as in Comparative Example 4. However, isopropyl myristate was replaced with oleic acid. This paper size applies to China National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling this page)

經濟部智慧財產局員工消費合作社印製 -23- 552143 A7 B7 五、發明説明（21 ) 試驗結果如表1所示。 (請先閱讀背面之注意事項再填寫本頁) 參考例1 m 〇 r a s t e p供與與實施例同法進行之試驗。 試驗結果如表1所示。 表1 經濟部智慧財產局員工消費合作社印製 實施例· 黏著劑組成 黏著層凝集 比較例 丙烯系 多價醇 脂肪 力（黏著層 剝離強 黏著劑 含有液 酸鹽 之附著殘留 度 (wt%) 體成分 (w t %) 防止性） (gf) (wt %) 實施例 1 49 GC 50 StMg 1 良好 2.22x 102 2 49 1，2，6-己 StMg 1 良好 2.38x 102 三醇50 1 50 GC 50 不良 比較例 2 49.95 GC 50 StMg0.05 不良 3 45 GC 50 StMg 5 塗工不可 4 49 IPM 50 StMg 1 不良 5 49 IOP 50 StMg 1 不良 6 49 OA 50 StMg 1 不良 參考例 - - - 良好 1.98x 102 1 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -24- 552143 A7 B7 經濟部智慧財產局Μ工消費合作社印製 五、發明説明（23 ) 實施例4 與實施例3同法進行後，製造膠帶製劑。惟，以辛酸 鈉取代硬脂酸鎂使用之。 結果如表2所示。 實施例5 與實施例3同法進行後，製造膠帶製劑，惟，以月桂 酸鈉取代硬脂酸鎂使用之。 結果如表2所示。 實施例6 與實施例3同法進行後，製造膠帶製劑。惟，以硬脂 酸鈉取代硬脂酸鎂使用之。 結果如表2所示。 實施例7 與實施例3同法進行後，製造膠帶製劑。惟，以硬脂 酸鋅取代硬脂酸鎂使用之。 結果如表2所示。 實施例8 與實施例3同法進行後，製造膠帶製劑。惟，以硬脂 酸鋁取代硬脂酸鎂使用之。 結果如表2所示。 (請先閱讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs -23- 552143 A7 B7 V. Description of Invention (21) The test results are shown in Table 1. (Please read the precautions on the back before filling out this page) Reference Example 1 m 〇 r a s t e p is used for the test performed in the same way as the example. The test results are shown in Table 1. Table 1 Example printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs · Composition of adhesives Adhesive layer agglomeration Comparative example Propylene-based polyvalent alcohols Fat force Ingredient (wt%) Preventive) (gf) (wt%) Example 1 49 GC 50 StMg 1 Good 2.22x 102 2 49 1,2,6-Hex StMg 1 Good 2.38x 102 Triol 50 1 50 GC 50 Bad Comparative Example 2 49.95 GC 50 StMg 0.05 Poor 3 45 GC 50 StMg 5 Coating impossibility 4 49 IPM 50 StMg 1 Poor 5 49 IOP 50 StMg 1 Poor 6 49 OA 50 StMg 1 Poor Reference Example---Good 1.98x 102 1 This paper size applies Chinese National Standard (CNS) A4 specification (210X 297 mm) -24- 552143 A7 B7 Printed by Intellectual Property Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of invention (23) Example 4 is the same as Example 3. After the method is performed, a tape preparation is produced. However, sodium octoate was used instead of magnesium stearate. The results are shown in Table 2. Example 5 was carried out in the same manner as in Example 3, and a tape preparation was produced. However, sodium laurate was used instead of magnesium stearate. The results are shown in Table 2. Example 6 After performing the same method as in Example 3, a tape preparation was produced. However, sodium stearate is used instead of magnesium stearate. The results are shown in Table 2. Example 7 After the same method as in Example 3, a tape preparation was produced. However, zinc stearate is used instead of magnesium stearate. The results are shown in Table 2. Example 8 After performing the same method as in Example 3, a tape preparation was produced. However, aluminum stearate is used instead of magnesium stearate. The results are shown in Table 2. (Please read the notes on the back before filling this page)

本纸張尺度適用中國國家標準（CNS ) Α4規格（210Χ 297公釐） -26- 552143 經濟部智慧財產局員工消費合作社印製 A7 ____B7五、發明説明（22) 〔註〕G C :甘油 S t M g :硬脂酸鎂 IPM:異丙基肉豆蔻酸酯 I〇P :異辛基棕櫚酸酯 〇A :油酸 不可塗工：產生凝膠化、調製黏著劑時使用有困難 ，因此無法塗工。 下記實施例3〜8係以含可多普落菲做爲藥理活性物 質之黏著劑使用後，針對6種脂肪酸金屬鹽之凝聚力改善 效果進行討論。又，實施例9，1 0中係於多價醇以外加 入脂肪酸酯做爲液體成份進行討論對於其凝聚力之影響。 比較例7〜8中係使用乙基乙醯醋酸酯鋁二異丙酸酯做爲 脂肪酸金屬鹽或無多價醇系與金屬螫合化合物之系進行檢 討。 實施例3 與實施例1同法進行後，製造膠帶。惟，乾燥後之黏 著層係由加入4 3重量％之丙烯系黏著劑、5 0重量％之 甘油及1重量％之硬脂酸鎂後，含6重量％之可多普落菲 之黏著性藥劑組成物所組成之黏著藥劑層者而取得膠帶製 劑者。 試驗結果如表2所示。 恭紙張尺度適用中國國家標準（CNS ) Α4規格（21〇Χ 297公釐） (請先閲讀背面之注意事項再填寫本頁) 裝.This paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm) -26- 552143 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 ____B7 V. Description of the invention (22) [Note] GC: Glycerol S t M g: magnesium stearate IPM: isopropyl myristate IOP: isooctyl palmitate OA: oleic acid non-paintable: difficult to use for gelation and adhesive preparation, so it cannot be used Painter. In Examples 3 to 8 below, the effect of improving the cohesive force of six kinds of fatty acid metal salts was discussed after using codopril as an adhesive containing a pharmacologically active substance. In addition, in Example 9, 10, a fatty acid ester was added as a liquid component in addition to a polyvalent alcohol, and the influence on the cohesive force was discussed. In Comparative Examples 7 to 8, ethyl acetoacetate aluminum diisopropylate was used as a fatty acid metal salt or a polyvalent alcohol-free and metal-chelating system was examined. Example 3 After performing the same method as in Example 1, an adhesive tape was produced. However, the adhesive layer after drying is obtained by adding 43% by weight of a propylene-based adhesive, 50% by weight of glycerin, and 1% by weight of magnesium stearate, and then containing 6% by weight of clodocrofier. Those who adhered to the drug layer composed of the drug composition and obtained the tape preparation. The test results are shown in Table 2. Christine paper size applies Chinese National Standard (CNS) Α4 specification (21〇 × 297 mm) (Please read the precautions on the back before filling this page).

、1T 線 -25- 552143 Α7 Β7 五、發明説明（24) 實施例9 (請先閲讀背面之注意事項再填寫本頁) 與實施例1同法進行後，製造膠帶製劑。惟，乾燥後 之黏者層係由含43重量％之丙烯系黏著劑、1〇重量％ 之山梨聚糖單月桂酸酯、4〇重量％之甘油、χ重量％之 硬脂酸錶及6重量％之可多普落菲之黏著性藥劑組成物所 組成之黏著藥劑層者，而取得膠帶製劑者。 試驗結果如表2所示。 實施例1〇 與實施例1同法進行後，製造膠帶。惟，乾燥後之黏 著層係由含43重量％之丙烯系黏著劑、1〇重量％之山 梨聚糖單月桂酸酯、20重量％之異丙基肉豆蔻酸酯、 2 0重量％之甘油及1重量％之硬脂酸鎂及6重量％之可 多普落菲之黏著性藥劑組成物所組成之黏著藥劑層者，而 取得膠帶製劑者。 結果如表2所示。 經濟部智慧財產局員工消費合作社印製 比較例7 與實施例3同法進行後，製造膠帶製劑。惟，以異丙 基肉豆蔻酸酯取代甘油使用之。 結果如表2所示。 比較例8 本纸張尺度適用中國國家標準（CNS ) Α4規格（210X297公釐） -27- 552143 A7 B7五、發明説明（25 ) 與實施例3同法進行後，製造膠帶製劑。惟，以山梨 聚糖單月桂酸酯取代甘油使用之。 結果如表2所示。 比較例9 與實施例3同法進行後，製造膠帶製劑。惟，未使用 硬脂酸鎂。 結果如表2所示。 比較例1 0 與實施例3同法進行後，製造膠帶製劑。惟，以乙基 乙醯醋酸酯鋁二異丙酸酯取代硬脂酸鎂使用之。 結果如表2所示。 (請先閱讀背面之注意事項再填寫本頁) 裝·、 1T line -25- 552143 Α7 Β7 V. Description of the invention (24) Example 9 (Please read the precautions on the back before filling in this page) The same method as in Example 1 was used to make the tape preparation. However, the dried adhesive layer is composed of 43% by weight of a propylene-based adhesive, 10% by weight of sorbitan monolaurate, 40% by weight of glycerin, χ% by weight of stearic acid, and 6 Those who obtained the adhesive agent layer composed of the adhesive medicinal composition of codoprolide by weight%, and who obtained the tape preparation. The test results are shown in Table 2. Example 10 After performing the same method as in Example 1, an adhesive tape was produced. However, the adhesive layer after drying is composed of 43% by weight of propylene-based adhesive, 10% by weight of sorbitan monolaurate, 20% by weight of isopropyl myristate, and 20% by weight of glycerol. And an adhesive agent layer composed of 1% by weight of magnesium stearate and 6% by weight of codoprapene's adhesive agent composition, and a person who obtained a tape preparation. The results are shown in Table 2. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. Comparative Example 7 The same procedure as in Example 3 was followed to produce a tape preparation. However, isopropyl myristate was used instead of glycerol. The results are shown in Table 2. Comparative Example 8 This paper size is in accordance with Chinese National Standard (CNS) A4 specification (210X297 mm) -27- 552143 A7 B7 V. Description of the invention (25) After the same method as in Example 3, a tape preparation is manufactured. However, sorbitan monolaurate was used instead of glycerol. The results are shown in Table 2. Comparative Example 9 After performing the same method as Example 3, a tape preparation was produced. However, magnesium stearate was not used. The results are shown in Table 2. Comparative Example 10 After performing the same method as in Example 3, a tape preparation was produced. However, instead of magnesium stearate, ethyl acetoacetate aluminum diisopropylate was used. The results are shown in Table 2. (Please read the notes on the back before filling this page)

、1T 經濟部智慧財產^7Μ工消費合作社印製 本纸張尺度適用中國國家標準（CNS ) Α4規格（210X297公釐） -28- 552143 A7 B7 五、發明説明（26 ) 經濟部智慧財產局員工消費合作社印製1. 1T Intellectual Property of the Ministry of Economic Affairs ^ Printed by 7M Industrial Consumer Cooperative Co., Ltd. This paper applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -28- 552143 A7 B7 V. Description of invention (26) Employees of the Intellectual Property Bureau of the Ministry of Economic Affairs Printed by Consumer Cooperatives

(請先閱讀背面之注意事項再填寫本頁) -裝· 訂 線 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -29- 552143 A7 B7 五、發明説明（27 ) 〔註〕G C :甘油 (請先閲讀背面之注意事項再填寫本頁) SPAN 20:山梨聚糖單月桂酸酯 I P Μ :異丙基肉豆蔻酸酯 s t M g :硬脂酸鎂 C p N a :辛酸鈉 R u N a :月桂酸鈉 S t N a :硬脂酸鈉 S t Z n :硬脂酸鋅 S t A 1 :硬脂酸鋁 A 1 :乙基乙醯醋酸酯鋁二異丙酸酯 K P :可多普落菲 下記實施例1 1係針對脂肪酸金屬鹽藥物皮膚滲透性 之影響進行討論。比較例1 1及1 2係以乙基乙醯醋酸酯 鋁二異丙酸酯做爲無脂肪酸金屬鹽系與藥物可相互作用之 金屬螫合化合物系進行討論。 經濟部智慧財產局員工消費合作社印製 實施例1 1 膠帶製劑之黏著藥劑層用塗佈液於1 5 . 3 g之丙烯 系黏著劑（共聚7wt%之甲基丙烯酸甲酯、90wt% 之2 -乙基己基丙烯酸酯、3 w t %之丙烯酸之後所取得 之丙烯系黏著劑溶於醋酸乙酯後之2 1 . 6 % d ο p狀者 使用之。）中加入0 · 1 g山梨聚糖單月桂酸酯、0.3 g甘油、〇 · 24g可多普落菲〇 _ 〇4g之硬脂酸鎂後 本紙張尺度適用中國國家標準（CNS ) A4規格（210 X 297公釐） -30- 552143 A7 B7 五、發明説明（28) ，更加入4 5 m 1之醋酸乙酯·乙醇混合液後（·醋酸乙酯 ••乙醇二2 : 1 ( v / v ))以勻漿器進行攪拌後調製之 〇 (請先閲讀背面之注意事項再填寫本頁) 此塗佈液於聚矽氧處理過之p E T薄膜上使乾燥後厚 度爲5 0 # m後以刮刀進行塗佈。塗佈液層於6 〇它下進 行乾燥3 0分’形成厚度5 0 // m之黏著藥劑層。此黏著 藥劑層貼於具透氣性之由聚對苯二甲酸乙酯纖維所組成之 織布上，供與進行滲透試驗。 試驗結果如表3所示。 比較例1 1 與實施例1 1同法進行後，製造膠帶製劑。惟，未使 用硬脂酸鎂。 試驗結果如表3所示。 比較例1 2 經濟部智慧財產局Μ工消費合作杜印製 與實施例1 1同法進行後，製造膠帶製劑。惟，以乙 基乙醯醋酸酯鋁二異丙酸酯取代硬脂酸鎂使用之。 結果如表3所示。 本紙張尺度適用中國國家標準（CNS ) Α4規格（210Χ 297公釐） -31 - 經濟部智慧財產局g(工消費合作社印製 552143 A7 ____ _ B7 五、發明説明（29 ) 表3 實施例 黏著藥劑層組成 凝集力（黏 可多普落菲 比較例 丙烯系 多價醇含有 脂肪 藥劑 著藥劑層 經皮吸收量 黏著劑 液體成分 酸鹽 (w ΐ %) 之附著殘 (U g / c m2 · (w t %) (w t %) (w t %) 留防止性） 24hr) 實施例 11 83 SPAN20 2.5 StMg 1 ΚΡ 6 良好 60 GC 7.5 比較例 11 84 SPAN20 2.5 - // 不良 57 GC 7.5 12 83 SPAN20 2.5 A1 1 // 不良 21 GC 7.5 〔註〕S P A N 2 0 :山梨聚糖單月桂酸酯 D C :甘油 S t M g :硬脂酸鎂 A 1 :乙基乙醯醋酸酯鋁二異丙酸酯 K P :可多普落菲 表3之含於黏著藥劑層之脂肪酸金屬鹽被證明不致降 低藥劑經皮吸收性，具提昇黏著藥劑層之凝聚力效果者。 下記實施例1 2〜1 7中針對6種吸收促進劑之吸收 促進效果更含該吸收促進劑之黏著劑凝聚力及透濕性進行 檢討。又，於比較例1 3〜1 8中吸收促進劑之有、無進 行與實施例1 2〜1 7之比較討論。比較例1 9中以其脂 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐^ (請先閲讀背面之注意事項再填寫本頁)(Please read the precautions on the back before filling out this page)-The binding and binding paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X 297 mm) -29- 552143 A7 B7 V. Description of the invention (27) [ Note) GC: Glycerin (please read the notes on the back before filling this page) SPAN 20: sorbitan monolaurate IP Μ: isopropyl myristate st M g: magnesium stearate C p N a : Sodium caprylate Ru Na: sodium laurate S t N a: sodium stearate S t Z n: zinc stearate S t A 1: aluminum stearate A 1: ethyl acetoacetate aluminum diiso Propionate KP: Kodoprofil. Example 11 1 discusses the effect of skin permeability of fatty acid metal salt drugs. Comparative Examples 1 and 12 were discussed using ethyl acetoacetate aluminum diisopropylate as a fatty acid-free metal salt system and a drug-interoperable metal chelate compound system. Printed in Example 1 by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 1 1 The coating solution for the adhesive agent layer of the tape preparation is 15.3 g of a propylene-based adhesive (copolymerized with 7 wt% of methyl methacrylate, 90 wt% of 2 -Ethylhexyl acrylate, 3 wt% acrylic acid, propylene-based adhesive obtained after dissolving in ethyl acetate, 2 1.6% d ο p-shaped one is used.) Added 0 · 1 g sorbitan Monolaurate, 0.3 g of glycerol, 0.24 g of codoprolide 〇_ 〇4 g of magnesium stearate This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) -30-552143 A7 B7 5. Description of the invention (28), after adding 4 5 m 1 of ethyl acetate · ethanol mixed solution (· ethyl acetate •• ethanol 2 2: 1 (v / v)) after stirring with a homogenizer Preparation 〇 (Please read the precautions on the back before filling in this page) This coating solution is applied on a poly-siloxane-treated p ET film to a thickness of 50 # m after drying, and then coated with a doctor blade. The coating liquid layer was dried at 60 ° C for 30 minutes' to form an adhesive agent layer having a thickness of 50 / m. This adhesive agent layer was affixed to a breathable woven fabric made of polyethylene terephthalate fibers for a penetration test. The test results are shown in Table 3. Comparative Example 11 was performed in the same manner as in Example 11 to produce a tape preparation. However, no magnesium stearate was used. The test results are shown in Table 3. Comparative Example 12 Du-printing by industrial and consumer cooperation of the Intellectual Property Bureau of the Ministry of Economic Affairs After performing the same procedure as in Example 11, a tape preparation was produced. However, aluminum acetoacetate aluminum diisopropylate was used instead of magnesium stearate. The results are shown in Table 3. This paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm) -31-Intellectual Property Bureau of the Ministry of Economic Affairs (printed by Industrial and Consumer Cooperatives 552143 A7 ____ _ B7) 5. Description of the invention (29) Table 3 Cohesive force of drug layer composition (Comparative example of viscodoloprolide, propylene-based polyhydric alcohol containing fatty drug, drug layer, percutaneous absorption of drug layer, adhesive liquid component (w ΐ%), adhesion residue (U g / c m2 · (wt%) (wt%) (wt%) retention prevention) 24hr) Example 11 83 SPAN20 2.5 StMg 1 ΚΡ 6 Good 60 GC 7.5 Comparative Example 11 84 SPAN20 2.5-// Bad 57 GC 7.5 12 83 SPAN20 2.5 A1 1 // Bad 21 GC 7.5 [Note] SPAN 2 0: Sorbitan monolaurate DC: Glycerin S t M g: Magnesium stearate A 1: Ethyl ethyl acetate ethyl diisopropylate KP: The metal salt of fatty acid contained in the adhesive drug layer of Cordoprolide Table 3 has been shown not to reduce the percutaneous absorption of the drug, and has the effect of improving the cohesive effect of the adhesive drug layer. Examples 1 to 2 in the following are directed to 6 types of absorption. The absorption promoting effect of the accelerator is more The adhesive cohesion and moisture permeability of the absorption enhancer were reviewed. The presence and absence of the absorption enhancer in Comparative Examples 1 3 to 18 were compared with those in Examples 1 2 to 17. Comparative Examples 1 to 9 Applicable to China National Standard (CNS) A4 specification (210X297 mm) with its paper size (please read the precautions on the back before filling this page)

-32- 552143 A7 B7 五、發明説明（3〇) (請先閱讀背面之注意事項再填寫本頁) 肪酸鹽有、無系中進行與實施例1 2之比較。更以無透濕 性膠帶製劑之 molastep做爲參考例2使用後，進行比較 討論。（以下，重量％以w t %記之。） 實施例1 2 共聚7wt%之甲基丙烯酸甲酯、90wt%之2— 乙基己基丙烯酸酯、3 w t %丙烯酸之後，取得1 5 . 3 g之丙烯系黏著劑（溶於醋酸乙酯之2 1 . 6 % d ο p ) (8 3 w t % )中，加入4 5 m 1醋酸乙酯·乙醇混合液 (醋酸乙酯：乙醇=2 : 1 ( v / v ))後，更加入 經濟部智慈財產局員工消費合作社印製 〇· lg (2 · 5wt%)之山梨聚糖單月桂酸酯、 〇.3g(7.5wt%)甘油、0.24g(6wt% )之可多普落菲、〇.〇4g(lwt%)之硬脂酸鎂（ S t M g )後，以勻漿器進行攪拌後，調製膠帶製劑之黏 著藥劑層用塗佈液。此塗佈液於聚矽氧處理過之P E 丁薄 膜上使乾燥後厚度爲5 0 // m後以刮刀進行塗佈，此塗佈 液層於6 0 t下進行乾燥3 0分鐘，形成厚度爲5 0 // m 之黏著藥劑層。此黏著藥劑層貼於由具透氣性之聚對苯二 甲酸乙酯纖維所組成之織布上，將此供與經皮吸收試驗、 凝聚力試驗及透濕度試驗。其結果如表4所示者。 實施例1 3 與實施例1 2同法進行後製造膠帶製劑。 惟，以山梨聚糖單油酸酯取代黏著藥劑層之山梨聚糖 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -33 - 552143 A7 _______B7 五、發明説明（31 ) 單月桂酸酯使用之。 結果如表4所示。 (請先閲讀背面之注意事項再填寫本頁) 實施例1 4 與實施例1 2同法進行後製造膠帶製劑。 惟’以山梨聚糖三油酸酯取代黏著藥劑層之山梨聚糖 單月桂酸酯使用之。 結果如表4所示。 實施例1 5 與實施例1 2同法進行後製造膠帶製劑。 1隹’以聚氧乙烯山梨聚糖單月桂酸酯取代黏著藥劑層 之山梨聚糖單月桂酸酯使用之。 結果如表4所示。 實施例1 6 與實施例1 2同法進行後，製造膠帶製劑。 經濟部智慧財產局員工消費合作社印製 惟’以聚氧乙烯山梨聚糖單棕櫚酸酯取代黏著藥劑層 之山梨聚糖單月桂酸酯使用之。 結果如表4所示。 實施例1 7 與實施例1 2同法進行後，製造膠帶製劑。 惟’以聚氧乙烯山梨聚糖單硬脂酸酯取代山梨聚糖單 本紙張尺度適用中國國家榡準（CNS ) A4規格（21〇Χ297公釐） -34- 552143 A7 __________B7 五、發明説明（32 ) 月桂酸酯使用之。 結果示於表4。 (請先閱讀背面之注意事項再填寫本頁) 比較例1 3 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 7 · 2 g之丙烯系黏 者劑與◦.24g之可多普落菲及〇.〇4g之硬脂酸鍾 者’乾燥後之黏著藥劑層爲含有9 3重量％之丙烯系黏著 劑與6重量％之可多普落菲及1重量％之硬脂酸鎂者。 結果示於表4。 比較例1 4 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑層用塗佈液係含有1 5 · 8 g之丙燃系 經濟部智慧財產局員工消費合作社印製 黏著劑與0·3g之甘油及0.24g可多普落菲與 〇 · 0 4 g之硬脂酸鎂者，乾燥之黏著藥劑層爲含有 8 5 _ 5重量％之丙烯系黏著劑與7 · 5重量％之甘油及 6重量％之可多普落菲與1重量％之硬脂酸鎂者。 結果如表4所不。 比較例1 5 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含有1 3 · 5 g之丙烯系 黏著劑與0 · 8 g之異丙基肉豆蔻酸酯及0 · 2 4 g之可 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -35- 552143 A7 B7 五、發明説明（33 ) 多普落菲與0 · 〇 4 g之硬脂酸鎂者，乾燥之黏著藥劑層 爲含有7 3重量％之丙烯系黏著劑與2 〇重量％之異丙基 肉丑蔻酸酯及6重量％之可多普落菲與1重量％之硬脂酸 錶者° 結果如表4所示。 比較例1 6 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 2 · 1 g之丙烯系黏 著劑與0 · 3 g之甘油及〇 · 8 g之異丙基肉豆蔻酸酯及 〇 · 24g之可多普落菲及〇 _ 〇4g之硬脂酸鎂者，乾 燥之黏著藥劑層爲含有6 5 . 5重量％之丙烯系黏著劑與 7 _ 5重量％之甘油及2 0重量％之異丙基肉豆蔻酸酯與 6重量％之可多普落菲及1重量％之硬脂酸鎂者。 試驗結果如表4所示。 比較例1 7 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含有1 5 . 8 g之丙烯系 黏著劑與0.4g之山梨聚糖單月桂酸酯與〇·24g之 可多普落菲，及0 · 0 4 g之硬脂酸鎂者，乾燥之黏著藥 劑層爲含8 3重量％之丙烯系黏著劑與1 〇重量％之山梨 聚糖單月桂酸酯及6重量％之可多普落菲及1重量％之硬 脂酸鎂者。 本紙張尺度適用中國國家標準（CNS ) A4規格（21〇X 297公釐） -------衣—— (請先閱讀背面之注意事項再填寫本頁)-32- 552143 A7 B7 V. Description of the invention (30) (Please read the precautions on the back before filling out this page) The comparison between the presence and absence of fatty acid salt and Example 12 is performed. The molastep of the non-moisture-permeable tape preparation was used as a reference example 2 for comparison and discussion. (Hereinafter, wt% is written in wt%.) Example 1 2 After copolymerizing 7wt% of methyl methacrylate, 90wt% of 2-ethylhexyl acrylate, and 3 wt% of acrylic acid, 15.3 g of Acrylic adhesive (dissolved in 2 1.6% d ο p) (83% by weight) of ethyl acetate, 4 5 m 1 of ethyl acetate · ethanol mixed solution (ethyl acetate: ethanol = 2: 1) (v / v)), added to the Consumer Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs to print lg (2.5 wt%) sorbitan monolaurate, 0.3 g (7.5 wt%) glycerin, 0.24 g (6wt%) of codoprolide, 0.04g (lwt%) of magnesium stearate (StMg), and then stirred with a homogenizer to prepare the adhesive agent layer of the tape preparation. Cloth fluid. This coating solution was applied on a polysiloxane-treated PE butyl film so that the thickness after drying was 50 0 // m, followed by coating with a doctor blade. The coating solution layer was dried at 60 t for 30 minutes to form a thickness. It is 5 0 // m adhesive agent layer. This adhesive agent layer was affixed to a woven fabric composed of breathable polyethylene terephthalate fibers, and this was used for a percutaneous absorption test, a cohesion test, and a moisture permeability test. The results are shown in Table 4. Example 1 3 was performed in the same manner as in Example 12 to produce a tape preparation. However, sorbitan is replaced by sorbitan monooleate. The paper size of this paper applies Chinese National Standard (CNS) A4 (210X297 mm) -33-552143 A7 _______B7 V. Description of the invention (31) Use it. The results are shown in Table 4. (Please read the precautions on the back before filling out this page.) Example 1 4 was performed in the same manner as in Example 12 to produce a tape preparation. However, sorbitan trioleate is used instead of sorbitan monolaurate which is attached to the drug layer. The results are shown in Table 4. Example 15 was performed in the same manner as in Example 12 to produce a tape preparation. In 1 隹 ', polyoxyethylene sorbitan monolaurate is used instead of sorbitan monolaurate which is attached to the drug layer. The results are shown in Table 4. Example 16 was performed in the same manner as in Example 12 to produce a tape preparation. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, but used sorbitan monolaurate instead of polyoxyethylene sorbitan monopalmitate. The results are shown in Table 4. Example 17 was performed in the same manner as in Example 12 to produce a tape preparation. However, the paper size of sorbitan single paper replaced with polyoxyethylene sorbitan monostearate is applicable to China National Standard (CNS) A4 (21〇297297 mm) -34- 552143 A7 __________B7 V. Description of the invention ( 32) Use laurate. The results are shown in Table 4. (Please read the precautions on the back before filling out this page.) Comparative Example 13 The same procedure as in Example 12 was followed to produce a tape preparation. However, the coating solution for the adhesive agent layer is a dried adhesive agent layer containing 17 · 2 g of a propylene-based adhesive, 24 g of clodrophene, and 0.04 g of stearic acid bell. It is a product containing 93% by weight of a propylene-based adhesive, 6% by weight of docopherol, and 1% by weight of magnesium stearate. The results are shown in Table 4. Comparative Example 14 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer contains 15 · 8 g of the propane-based combustion agent of the Intellectual Property Bureau of the Ministry of Economic Affairs and the Consumer Cooperatives printed adhesives and 0.3 g of glycerol and 0.24 g of clodocrofil and 0.0 In the case of 4 g of magnesium stearate, the dried adhesive agent layer contains 85-5 wt% of a propylene-based adhesive, 7.5 wt% of glycerol, and 6 wt% of clodocrophen and 1 wt% of Those who are magnesium stearate. The results are shown in Table 4. Comparative Example 15 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer is a composition containing 1 3 · 5 g of propylene-based adhesive, 0 · 8 g of isopropyl myristate, and 0 · 2 4 g. CNS) A4 specification (210X297 mm) -35- 552143 A7 B7 V. Description of the invention (33) For doprofen and 0. 〇4 g of magnesium stearate, the dry adhesive agent layer contains 73% by weight The results are shown in Table 4 with a propylene-based adhesive, 20% by weight of isopropyl myristate, and 6% by weight of docopherol and 1% by weight of stearic acid. Comparative Example 16 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 12 · 1 g of a propylene-based adhesive, 0 · 3 g of glycerin, 0.8 g of isopropyl myristate, and 0.24 g of doporoxol. For phenanthrene and 〇_〇4g of magnesium stearate, the dried adhesive agent layer contains 65.5% by weight of propylene-based adhesive and 7_5% by weight of glycerin and 20% by weight of isopropyl nutmeg. Acid ester with 6% by weight of docopherol and 1% by weight of magnesium stearate. The test results are shown in Table 4. Comparative Example 17 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 15.8 g of an propylene-based adhesive, 0.4 g of sorbitan monolaurate, and 0.24 g of clodocrophen, and 0.44 g of For magnesium stearate, the dried adhesive agent layer is composed of 83% by weight of a propylene-based adhesive and 10% by weight of sorbitan monolaurate and 6% by weight of codoprolide and 1% by weight of Those who are magnesium stearate. This paper size applies to China National Standard (CNS) A4 (21〇X 297 mm) ------- clothing-(Please read the precautions on the back before filling this page)

、1T 經濟部智慧財產局g(工消費合作社印製 -36- 經濟部智慧財產局g(工消費合作社印製 552143 A7 B7_ 五、發明説明（34 ) 試驗結果如表4所示。 比較例1 8 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 5 . 8 g之丙烯系黏 著劑與0 . 4 g之聚氧乙烯山梨聚糖單月桂酸酯與 〇·24g之可多普落菲及0·〇4g之硬脂酸鎂者，乾 燥之黏著藥劑層爲含有8 3重量％之丙烯系黏著劑與1 〇 重量％之聚氧乙烯山梨聚糖單月桂酸酯及6重量％之可多 普落菲與1重量％之硬脂酸鎂者。 試驗結果如表4所示。 比較例1 9 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含有1 5 . 6 g之丙烯％ 黏著劑與〇 · 1 g之山梨聚糖單月桂酸酯及〇 . 3 g之甘 油與0 · 2 4 g之可多普落菲者，乾燥之黏著藥劑層爲含 8 4重量％之丙嫌系黏著劑與2 · 5重量％之山梨聚糖:單 月桂酸酯及7 · 5重量％之甘油與6重量％之可多普落;菲 者。 試驗結果如表4所示。 參考例2 molastep與實施例相同供與試驗。試驗結果如表4 —丨丨 - . 本紙張I度適用中國國家標準（CNS ) A4規格（210X 297公釐）'- C請先閱讀背面之注意事項再填寫本頁}1T Intellectual Property Bureau of the Ministry of Economic Affairs (printed by the Industrial and Consumer Cooperatives-36- Intellectual Property Bureau of the Ministry of Economic Affairs (printed by the Industrial and Consumer Cooperatives) 552143 A7 B7_ 5. Description of the invention (34) The test results are shown in Table 4. Comparative Example 1 8 The same procedure as in Example 12 was followed to produce a tape preparation. However, the coating solution for the adhesive agent layer contained 15.8 g of a propylene-based adhesive and 0.4 g of polyoxyethylene sorbitan monolauric acid. For esters and 0.24 g of codoporfi and 0.04 g of magnesium stearate, the dry adhesive agent layer contains 83% by weight of a propylene-based adhesive and 10% by weight of polyoxyethylene sorbitan. Sugar monolaurate, 6% by weight of codoprylphene and 1% by weight of magnesium stearate. The test results are shown in Table 4. Comparative Examples 19 and 12 were prepared in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 15.6 g of propylene% adhesive and 0.1 g of sorbitan monolaurate and 0.3 g of glycerol and 0.24 g of For Doppler, the dried adhesive agent layer contains 84% by weight of C-type adhesive and 2.5% by weight of sorbitan: single month Esters and 7.5 wt% glycerol and 6 wt% codoprolide. The test results are shown in Table 4. Reference Example 2 Molastep is the same as the examples for the test. The test results are shown in Table 4-丨-. This paper is suitable for Chinese National Standard (CNS) A4 (210X 297mm) I- '. Please read the notes on the back before filling in this page}

-37- 552143 A7 B7 五、發明説明（35 ) 所示者。 (請先閲讀背面之注意事項再填寫本頁) 下記實施例1 8〜1 9中，針對含山梨聚糖單月桂酸酯 之添加量與可多普落菲滲透量相關性，該吸收促進劑之黏 著藥劑層之凝聚力及透濕性進行討論。 實施例1 8 與實施例1 2同法進行製造膠帶製劑。 惟’黏著藥劑層用塗佈液爲含有1 4 . 9 g之丙烯系 黏著劑與0 · 2 g之山梨聚糖單月桂酸酯及〇 · 3 g之甘 油與0 · 24g之可多普落菲及〇 · 〇4g之硬脂酸鎂者 ’乾燥之黏著藥劑層爲含有8 0 · 5重量％之丙烯系黏著 劑與5重量％之山梨聚糖單月桂酸酯與7·5重量％之甘 油、6重量％之可多普落菲與1重量％之硬脂酸鎂者。 試驗結果如表4所示者。 實施例1 9 與實施例1 2同法進行後製造膠帶製劑。 經濟部智慧財產局R工消費合作社印製 惟，黏著藥劑層用塗佈液爲含有1 3 . 9 g之丙烯系 黏著劑與0 · 4 g之山梨聚糖單月桂酸酯與〇 · 3 g之甘 油及0 · 24g之可多普落菲及0 . 〇4g之硬脂酸鎂者 ，乾燥之黏著藥劑層爲含有7 5 · 5重量％之丙烯系黏著 劑與1 0重量％之山梨聚糖單月桂酸酯與7 . 5重量％之 甘油及6重量％之可多普落菲與1重量％之硬脂酸鎂者。 試驗結果如表4所示。 本纸張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -38- 552143 A7 B7 _ 五、發明説明（36 ) 下記實施例2 0中，針對甘油之添加量與可多普落菲 滲透量相關性（實施例1 2相比較），含該吸收促進劑之 黏著藥劑層之凝聚力及透濕性進行討論。 實施例2 0 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 3 · 9 g之丙烯系黏 著劑與0 · 1 g之山梨聚糖單月桂酸酯與〇 . 6 g之甘油 及〇·24g之可多普落菲與0.04g之硬脂酸鎂者， 乾燥之黏著藥劑層爲含有7 5 · 5重量％之丙烯系黏著劑 與2 . 5重量％之山梨聚糖單月桂酸酯及1 5重量％之甘 油與6重量％之可多普落菲及1重量％之硬脂酸鎂者。 試驗結果如表4所示。 下記實施例2 1〜2 2中，針對異丙基肉豆蔻酸酯之 添加量與可多普落菲滲透量之相關性，含該吸收促進劑之 黏著藥劑層之凝聚力及透濕性進行討論。 實施例2 1 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 3 · 5 g之丙烯系黏 著劑與0 _ 1 g之山梨聚糖單月桂酸酯與〇 . 3 g之甘油 及0 · 4g之異丙基肉豆蔻酸酯及〇 · 2 4g之可多普落 菲與0 · 0 4 g之硬脂酸鎂者，乾燥之黏著藥劑層爲含 7 3重量％之丙烯系黏著劑與2 · 5重量％之山梨聚糖單 本紙張尺度適用中國國家標準（CNS) A4規格（210x297公釐） (請先閱讀背面之注意事項再填寫本頁)-37- 552143 A7 B7 V. The description of the invention (35). (Please read the precautions on the back before filling this page.) In the following Examples 1 to 19, the absorption enhancer is related to the amount of sorbitan-containing monolaurate and the amount of docopherol permeation. The cohesion and moisture permeability of the adhesive agent layer will be discussed. Example 18 A tape preparation was produced in the same manner as in Example 12. However, the coating solution for the adhesive agent layer is composed of 14.9 g of a propylene-based adhesive and 0.2 g of sorbitan monolaurate, 0.3 g of glycerol, and 0,24 g of codoprolide. Phenanthrene and 0.04 g of magnesium stearate are dried adhesive agent layers containing 80.5% by weight of propylene-based adhesive and 5% by weight of sorbitan monolaurate and 7.5% by weight of Glycerin, 6% by weight of clodocrophen and 1% by weight of magnesium stearate. The test results are shown in Table 4. Example 19 was performed in the same manner as in Example 12 to produce a tape preparation. Printed by the R Industrial Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, but the coating solution for the adhesive agent layer contains 3.9 g of a propylene-based adhesive and 0.4 g of sorbitan monolaurate and 0.3 g Of glycerol and 0. 24 g of codopramfil and 0.04 g of magnesium stearate, the dry adhesive agent layer is composed of 7.5 · 5% by weight of a propylene-based adhesive and 10% by weight of sorbitan. Sugar monolaurate and 7.5% by weight of glycerol and 6% by weight of docopherol and 1% by weight of magnesium stearate. The test results are shown in Table 4. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -38- 552143 A7 B7 _ V. Description of the invention (36) In the following Example 20, the amount of glycerol and clodoprofil Correlation of permeation amount (compared with Examples 12 and 2), cohesion and moisture permeability of the adhesive agent layer containing the absorption enhancer will be discussed. Example 20 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 13.9 g of a propylene-based adhesive and 0. 1 g of sorbitan monolaurate, 0.6 g of glycerol, and 0.24 g of codoprolide. In the case of phenanthrene and 0.04g of magnesium stearate, the dried adhesive agent layer contains 75.5% by weight of a propylene-based adhesive and 2.5% by weight of sorbitan monolaurate and 15% by weight of glycerol. With 6% by weight of clodocrophen and 1% by weight of magnesium stearate. The test results are shown in Table 4. In Examples 2 to 2 below, the correlation between the amount of isopropyl myristate added and the amount of docopherol permeate, the cohesion and moisture permeability of the adhesive agent layer containing the absorption enhancer are discussed. . Example 21 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 13.5 g of an propylene-based adhesive and 0 -1 g of sorbitan monolaurate, 0.3 g of glycerol, and 0.4 g of isopropyl meat. For myristic acid ester and 0.24 g of docopherol and 0.4 g of magnesium stearate, the dry adhesive agent layer is 73% by weight of propylene-based adhesive and 2.5% by weight of The sorbitan single paper size applies to the Chinese National Standard (CNS) A4 (210x297 mm) (Please read the precautions on the back before filling this page)

經濟部智慈財產局員工消費合作社印製 -39 - 經濟部智慧財產局員工消費合作社印製 552143 A7 ----------B7 五、發明説明（37 ) 月桂酸酯及7·5重量％之甘油及1〇重量％之異丙基肉 S寇酸酯與6重量％之可多普落菲與1重量％之硬脂酸鎂 者。 試驗結果如表4所示。 實施例2 2 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 1 · 7 g之丙烯系黏 著劑與0 · 1 g之山梨聚糖單月桂酸酯與〇 · 3 g之甘油 及0 . 8 g之異丙基肉豆蔻酸酯與〇 . 2 4 g之可多普落 菲及〇 · 〇 4 g之硬脂酸鎂者，乾燥之黏著藥劑層爲含有 6 3 · 5重量％之丙烯系黏著劑與2 · 5重量％之山梨聚 糖單月桂酸酯及7 . 5重量％之甘油與2 0重量％之異丙 基肉豆蔻酸酯及6重量％之可多普落菲及1重量％之硬脂 酸鎂者。 試驗結果如表4所示。 比較例2 0 與實施例1 2同法進行後製造膠帶製劑。 惟’黏著藥劑層用塗佈液爲含1 3 · 5 g之丙烯系黏 著劑與0 · 1 g之山梨聚糖單月桂酸酯與〇 · 4 g之異丙 基肉豆蔻酸酯與〇·24g之可多普落菲與〇·〇4g之 硬脂酸鎂者’乾燥之黏著藥劑層爲含有8 〇 · 3重量％之 丙烯系黏著劑與2 · 5重量％之山梨聚糖單月桂酸酯與 1—一 本紙適财關緖準（CNS) A4規格（21GX 297公慶） (請先閱讀背面之注意事項再填寫本頁)Printed by the Employees 'Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs-39-Printed by the Consumers' Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 552143 A7 ---------- B7 V. Description of the Invention (37) Laurate and 7 · 5% by weight of glycerol and 10% by weight of isopropyl meat S-coate and 6% by weight of docopherol and 1% by weight of magnesium stearate. The test results are shown in Table 4. Example 22 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 1 · 7 g of a propylene-based adhesive and 0 · 1 g of sorbitan monolaurate, 0.3 g of glycerol, and 0.8 g of isopropyl. With myristic acid ester and 0.24 g of codopramide and 0.04 g of magnesium stearate, the dry adhesive agent layer is a propylene-based adhesive containing 63.5% by weight and 2 · 5% by weight of sorbitan monolaurate and 7.5% by weight of glycerol and 20% by weight of isopropyl myristate and 6% by weight of docopherol and 1% by weight of stearic acid Magnesium. The test results are shown in Table 4. Comparative Example 20 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 13.5 g of an propylene-based adhesive and 0. 1 g of sorbitan monolaurate and 0.4 g of isopropyl myristate and 0 · 24 g of codoprysene and 0.04 g of magnesium stearate are dried adhesive agent layers containing 80.3 wt% of a propylene-based adhesive and 2.5 wt% of sorbitan monolauric acid. Ester and 1—One Paper Applicable Financial Standards (CNS) A4 Specification (21GX 297 Public Holiday) (Please read the precautions on the back before filling this page)

-40 - 552143 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明説明（38) 10重量％之異丙基肉豆蔻酸酯及6重量％之可多普落菲 及1重量％之硬脂酸鎂者。 試驗結果如表4所示。 下記實施例2 3〜2 4中針對1 ，2，6 -己三醇取 代甘油，且，異辛基棕櫚酸酯取代異丙基肉豆蔻酸酯時之 可多普落菲滲透性，含該吸收促進劑之黏著藥劑層之凝聚 力及透濕性進行討論。 實施例2 3 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 5 · 3 g之丙烯系黏 著劑與0 · 1 g之山梨聚糖單月桂酸酯及〇 · 3 g之1， 2，6 -己三醇及〇 · 24g之可多普落菲，與〇 · 04 g之硬脂酸鎂者，乾燥之黏著藥劑層爲含有8 3重量％之 丙烯系黏著劑與2 · 5重量％之山梨聚糖月桂酸酯及 7 · 5重量％之1 ，2，6 —己三醇與6重量％之可多普 落菲及1重量％之硬脂酸鎂者。 西式驗結果如表4所示。 實施例2 4 與實施例1 2同法進行後，製造膠帶製劑。 惟’黏著藥劑層用塗佈液爲含1 3 · 5 g之丙烯系黏 著劑與0 . 1 g之山梨聚糖單月桂酸酯及〇 · 3 g之甘油 與〇 · 4 g之異辛基棕櫚酸酯與〇 . 2 4 g之可多普落菲 (請先閱讀背面之注意事項再填寫本頁)-40-552143 Printed by A7 B7, Consumer Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the invention (38) 10% by weight of isopropyl myristate and 6% by weight of codoprolide and 1% by weight of hard Those who are magnesium stearate. The test results are shown in Table 4. In the following Examples 2, 3 to 24, the percolafil permeability when 1,2,6-hexanetriol is substituted for glycerol and isopropyl myristate is substituted by isooctyl palmitate is contained. The cohesion and moisture permeability of the adhesive agent layer of the absorption accelerator will be discussed. Example 2 3 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer contains 15 · 3 g of a propylene-based adhesive and 0 · 1 g of sorbitan monolaurate and 0.3 g of 1,2,6-hexanetriol and 〇24g of codoprolide and 0.04g of magnesium stearate, the dry adhesive agent layer contains 83% by weight of propylene-based adhesive and 2.5% by weight of sorbitan lauric acid Esters and 7.5 wt% of 1,2,6-hexanetriol and 6 wt% of clodocrophen and 1 wt% of magnesium stearate. Western test results are shown in Table 4. Example 24 was carried out in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 13.5 g of a propylene-based adhesive and 0.1 g of sorbitan monolaurate, 0.3 g of glycerol, and 0.4 g of isooctyl. Palmitate and 0.24 g of clodocrophen (please read the precautions on the back before filling this page)

本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -41 - 43 1X 2 5 5This paper size applies to China National Standard (CNS) A4 (210X297mm) -41-43 1X 2 5 5

A C 五、發明説明（39) (請先閱讀背面之注意事項再填寫本頁) 及0 . 0 4 g之硬脂酸鎂者，乾燥黏著藥劑層爲含有7 3 重量％之丙烯系黏著劑與2·5重量％之山梨聚糖單月桂 酸醋及7·5重量％之甘油與1〇重量％之異辛基棕櫚酸 醋及6重量％之可多普落菲與1重量％之硬脂酸鎂者。 試驗結果如表4所示。 表 4 添加劑 可多普落菲 (ketoprofen) 菲透過量 (β g/cm2* 24hr) 凝集力（黏著 藥劑層之附 著殘留防止 性） 透濕度 (g/m2· 曰） 實施例 12 SPAN20 2.5wt% 80 〇 743 GC 7.5 // StMg l.O 〃 13 SPAN80 2.5wt% 60 〇 762 GC 7.5 // StMg l.O // 14 SPAN85 2.5wt% 40 〇 757 GC 7.5 // StMg l.O // 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標率（CNS ) A4規格（210X297公釐） -42- 552143 A7 B7 五、發明説明（4〇 經濟部智慧財產局員工消費合作社印製 ,^1 蟀〜. oo ON 寸 CN tn (N un 寸 Ο wn ON oo v〇 CN vn r- 卜 v〇 Γ- m 寸 o o m <N CN r- o OO CO 卜 寸 寸 攤餿A ** m ¢1 R ^ g 撇β Sffl 骧蘅 〇 〇 〇 〇 〇 〇 〇 X X X 〇 〇 〇 M _ 賴二 m ^ 111! · T*nv rv, ^ 〇 Hi 'So 你a ^^ m un oo CN 寸 <N 卜 卜 o CM o v〇 l〇 cn <N oo o 寸 CN m f-H Ο ν〇 m □ 遐 s n i〇 . 〇 * c-' CN 一 〇 Z： m m bD r, U -H ^ f ^ t un , 〇 ' r-- Oi — 〇 寸 UJ PJ ba r. U - H o ^ Ϊ > > ^ ^ ^ • r-' CN 一 〇 VO PJ (ϋ bfl r. U -H ^ A 〇 bfl 00 、^ 〇 卜— U) u ^ 〇 ^ Ο CN ^ OJ) ^ oo HH === 5： 〇· 〇 r-二 bfl U Oh "： 〇 ^ ^ ^ o o ^ o CSJ 2； c ^ 00 一 oo t ^ 〇 〇 r—^ · r—1 o CN ω芝 9-. oo <N 〇 CN < CO ^ 〇 # 炤 Μ vn — 〇 CN 〇 ^ -^ 〇 彡c- · ο — ο οι Ζ < ωι Ρ. S c/〇 CJ *-* Ο ^ / m v〇 卜 m 寸 v〇 r- OO ON CN OO CN m M fc S JJ {§ 飆 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -43- 552143 A7 B7 五、發明説明（41 經濟部智慧財產局員工消費合作社印製 透濕度 (g/m2·日） 787 721 761 743 744 723 凝集力（黏著藥劑層 之附著殘留防止性） 〇 〇 〇 X 〇 〇 可多普落菲透過量 (//g/cm2· 24 hr) 100 105 121 oo o 添加劑 SPAN20 2.5wt% GC 15 〃 StMg 1.0 " ^ ^ ^ . O 〇 • ^ CSJ — O CNl 艺 〇〇 ΗΉ C/^ ^ ^ ^ 4—» «Ο . O 〇 • csi * CM ^ o csi ^ DJO ^ O P-. ^ ⑺◦ C/0 SPAN20 2.5wt% IPM 10 〃 StMg 1.0 " SPAN20 2.5 w t % 1,2,6- 7.5 " 1，2,6-己二醇 StMg 1.0 " ^ ^ ^ ^ 4-^ ^ u〇 〇 〇 w . H · 〇 CNl < ⑶ ^ u ^ s 〜2 g / o Csl CNl CsJ 比較例 20 CO CNl 實施例 實施例 1 ! (請先閱讀背面之注意事項再填寫本頁)AC V. Description of the invention (39) (Please read the precautions on the back before filling in this page) and 0.04 g of magnesium stearate. The dry adhesive agent layer is a propylene-based adhesive containing 73% by weight and 2.5% by weight of sorbitan monolaurate and 7.5% by weight of glycerol and 10% by weight of isooctyl palmitate and 6% by weight of docopherol and 1% by weight of stearin Magnesium acid. The test results are shown in Table 4. Table 4 Additive ketoprofen phenanthrene permeability (β g / cm2 * 24hr) Cohesion (prevention of adhesion and residue of adhesive agent layer) Moisture permeability (g / m2 ·) Example 12 SPAN20 2.5wt% 80 〇743 GC 7.5 // StMg lO 〃 13 SPAN80 2.5wt% 60 〇762 GC 7.5 // StMg lO // 14 SPAN85 2.5wt% 40 〇757 GC 7.5 // StMg lO // Employee Consumption Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs Printed paper scales are applicable to China National Standards (CNS) A4 specifications (210X297 mm) -42- 552143 A7 B7 V. Description of the invention (40 printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, ^ 1 蟀 ~. Oo ON inch CN tn (N un inch 〇 wn ON oo v〇CN vn r- v v〇Γ- m inch oom < N CN r- o OO CO 寸 inch inch stall A ** m ¢ 1 R ^ g β β Sffl 骧 蘅 〇〇〇〇〇〇〇〇〇〇XXX 〇〇〇〇M _ Lai Erm ^ 111! · T * nv rv, ^ 〇Hi 'So you a ^^ m un oo CN inch < N 卜卜 o CM ov 〇l〇cn < N oo o inch CN m fH Ο ν〇m □ siani. 〇 * c- 'CN 〇Z: mm bD r, U -H ^ f ^ tu n, 〇 'r-- Oi — 〇 inch UJ PJ ba r. U-H o ^ Ϊ > > ^ ^ ^ • r-' CN 〇VO PJ (ϋ bfl r. U -H ^ A 〇bfl 00, ^ 〇 卜 — U) u ^ 〇 ^ 〇 CN ^ OJ) ^ oo HH === 5: 〇 · 〇r- 二 bfl U Oh ": 〇 ^ ^ ^ oo ^ o CSJ 2; c ^ 00 Oo t ^ 〇〇r— ^ · r-1 o CN ω 芝 9-. Oo < N 〇CN < CO ^ 〇 # 炤 Μ vn — 〇CN 〇 ^-^ 〇 彡 c- · ο — ο οι ZO < ωι Ρ. S c / 〇CJ *-* Ο ^ / mv〇 卜 m 寸 v〇r- OO ON CN OO CN m M fc S JJ {§ Biao (Please read the notes on the back before filling in (This page) This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297 mm) -43- 552143 A7 B7 V. Description of the invention (41 Printed by Moisture Permeability (g / m2 · Day ) 787 721 761 743 744 723 Cohesion (prevention of adhesion and adhesion of the adhesive agent layer) 〇〇〇X 〇〇 The amount of percolafil (// g / cm2 · 24 hr) 100 105 121 oo o Additive SPAN20 2.5 wt% GC 15 〃 StMg 1.0 " ^ ^ ^. O 〇 • ^ CSJ — O CNl 艺 〇 ΗΉ C / ^ ^ ^ ^ 4— »« Ο. O 〇 • csi * CM ^ o csi ^ DJO ^ O P-. ^ C◦ C / 0 SPAN20 2.5wt% IPM 10 〃 StMg 1.0 " SPAN20 2.5 wt% 1,2,6- 7.5 " 1,2,6-hexanediol StMg 1.0 " ^ ^ ^ ^ 4- ^ ^ u〇〇〇w. H · 〇CNl < ⑶ ^ u ^ s ~ 2 g / o Csl CNl CsJ Comparative Example 20 CO CNl Example Example 1! (Please read the precautions on the back before filling this page)

本纸張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -44 - 552143 經濟部智慧財產局員工消費合作社印製This paper size applies to China National Standard (CNS) A4 (210X 297 mm) -44-552143 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs

i '發明説明（42) 〔註〕S P A N 2 0 S P A N 8 0 S P A N 8 5 G C S t M g Tween 20 Tween 4 0 Tween 6 0 I PM I〇P A7 B7 山梨聚糖單月桂酸酯 山梨聚糖單油酸酯 山梨聚糖三油酸酯 甘油 硬脂酸鎂 聚氧乙烯山梨聚糖單月桂酸酯 聚氧乙烯山梨聚糖單棕櫚酸酯 聚氧乙烯山梨聚糖單硬脂酸酯 異丙基肉豆蔻酸酯 異辛基棕櫚酸酯 下記實施例2 5中，針對以非類固醇系消炎鎭痛劑之 felvinack取代可多普落菲時之滲透性，含該藥劑之黏著 藥劑層之凝聚力及透濕性進行討論。 實施例2 5 與實施例1 2同法進行後，製造膠帶製劑。 惟’黏著藥劑用塗佈液爲含丨6 · 4 g之丙烯系黏著 劑與〇 · 1 g之山梨聚糖單月桂酸酯及〇 · 3 g之甘油與 〇.〇 4 g之felvinack與0 · 0 4 g之硬脂酸鎂者， 乾燥Z黏者藥劑層爲含有8 8 · 5重量％之丙烯系黏著劑 與2 · 5重量％之山梨聚糖單月桂酸酯，7 · 5重量％之 甘油與0 · 5重量％之felvinack及1重量％之硬脂酸 鎂者。試驗結果如表5所示。 本紙張尺度適用宁國國家榡準（CNS ) A4規格（210X 297公釐） (請先閱讀背面之注意事項再填寫本頁) 丁 -45 552143 A7 B7 五、發明説明（43 ) 參考例3 celtach消炎貼布（商標、貼布劑）與實施例2 5相 同供與felvinac滲透試驗及凝聚力試驗。 試驗結果如表5所示。 表 5 添加劑 felvinac 透過量 (β g/cm2* 24hr) 凝集力 透濕度 (g/m2· 曰） 實施例25 SPAN20 2.5wt% GC 7.5// StMg l.〇// 4.2 良好 722 參考例3 c e 11 a c h消炎貼 布（商標） 4.0 良好 睡 註〕S P A N 2 0 ··山梨聚糖單月桂酸酯 G C :甘油 S t M g :硬脂酸鎂 下記實施例2 6及2 7中，針對以雌激素做爲女性激 素劑使用時之黏著藥劑層之雌激素滲透性，含該藥劑之黏 著藥劑層之凝聚力及透濕性進行討論。且，爲達成高滲透 性之雌激素於下記實施例2 8中添加油酸乙酯、聚乙烯吡 本紙張尺度適用中國國家標準（CNS ) A4規格（210Χ 297公釐） (請先閲讀背面之注意事項再填寫本頁) 裝. 訂 經濟部智慈財產局員工消費合作社印製 -46- 552143 A7 B7 五、發明説明（44) 咯烷酮系中亦進行相同討論。 實施例2 6 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含有1 4 · 0 g之丙烯系 黏著劑與0 · 1 g之山梨聚糖單月桂酸酯，及〇 . 3 g之 甘油與0 · 128g之雌激素及〇 · 〇4g之硬脂酸鎂者 ’乾燥之黏著藥劑層爲含有7 5 . 8重量％之丙烯系黏著 劑與2 · 5重量％之山梨聚糖單月桂酸酯及7 _ 5重量％ 之甘油與3 . 2重量％之雌激素及1重量％之硬脂酸鎂者 。試驗結果如表6所示。 實施例2 7 與實施例1 2同法進行後，製造膠帶製劑。 惟，黏著藥劑層用塗佈液爲含1 4 · 0 g之丙烯系黏 著劑與0 _ 1 g之山梨聚糖單月桂酸酯與〇 . 3 g之甘油 及0 · 4g之異丙基肉豆蔻酸酯與〇 · l28g之 雌激素及〇 · 〇 4 g之硬脂酸鎂者。乾燥之黏著藥劑層爲 7 5 · 8重量％之丙烯系黏著劑與2 . 5重量％之山梨聚 糖單月桂酸酯及7·5重量％之甘油與10重量％之異丙 基肉豆蔻酸酯及3 ·2重量％之雌激素與1重量％之硬脂 酸者。試驗結果如表6所示。 實施例2 8 本紙張尺度適用中國國家標準（CNS ) a4規格（2i〇X 297公釐） (請先閱讀背面之注意事項再填寫本頁} .裝· 訂 經濟部智慧財產局員工消費合作社印製 -47- 552143 Μ —-----Β7 _ 五、發明説明（45) 與實施例1 2同法進行後製造膠帶製劑。 (請先閱讀背面之注意事項再填寫本頁) 惟，黏著藥劑層用塗佈液爲含有8 . 3 g之丙烯系黏 著劑與0 · 2 g之山梨聚糖單月桂酸酯及〇 · 4 g二異丙 基肉豆蔻酸酯，與〇 · 6g之1 ，2，6 —己三醇及 〇 · 6 g之油酸乙酯及〇 · 2 4 g之聚乙烯吡咯烷酮與 〇 · 1 6 g之雌激素及〇 · 0 4 g之硬脂酸鎂者，乾燥之 黏著藥劑層爲含有4 5重量％之丙烯系黏著劑與5重量％ 之山梨聚糖單月桂酸酯及10重量％之異丙基肉豆蔻酸酯 與1 5重量％之1 ，2，6 -己三醇及1 5重量％之油酸 乙酯及6重量％之聚乙烯吡咯烷酮及4重量％之 雌激素及1重量％之硬脂酸鎂者。試驗結果如表6所示。 比較例2 1 與實施例1 2同法進行後，製造膠帶製劑。 經濟部智慧財產局W工消費合作社印製 惟，黏著藥劑用塗佈液爲含有1 7 . 7 g之丙烯系黏 著劑與0 · 1 2 8 g之雌激素及〇 · 0 4 g之硬脂酸鎂者 ’乾燥之黏著藥劑層爲含有9 5 · 8重量％之丙烯系黏著 劑與3 · 2重量％之雌激素及1重量％之硬脂酸鎂者。 目式驗結果如表6所不。 本纸張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -48- 552143 Μ Β7 五、發明説明（46) 表 6 經濟部智慧財產局員工消費合作社印製 \ 添加劑 雌激素 estradiol 透過量（ ng/cm2. 48hr) 凝集力(黏著 藥劑層之附著 殘留防止性） 透濕度 (g/m2* 曰） 實施例 26 SPAN20 2.5wt% 20 〇 724 GC 7.5// StMg 1.0// 27 SPAN20 2.5wt% 15.7 〇 716 GC 2.5// IPM 10// StMg 1.0// 28 SPAN20 5wt% 35 〇 720 IPM 10 〃 1,2,6- 15 // 1，2,6-己 三醇 〇E 15 〃 PVP 6 f StMg // 比較例21 StMg 1.0// 1.1 〇 515 〔註〕S P A Ν 2 0 :山梨聚糖單月桂酸酯 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -49- 552143 A7 B7 i、發明説明（47) G C :甘油 S t M g :硬脂酸鎂 IPM :異丙基肉豆蔻酸酯 0 E :油酸乙酯 P v p :聚乙烯吡咯烷酮 下記實施例2 9〜3 0中，針對以雄激素做爲男性激 素使用時之滲透性，含該藥劑之黏著藥劑層之凝聚力及透 濕性進行討論。 實施例2 9 與實施例1 2同法進行後製造膠帶製劑。 惟’黏著藥劑層用塗佈液爲含有i 5 · 9 g之丙烯系 黏著劑與0 · 1 g之山梨聚糖單月桂酸酯與〇 · 3 g之甘 油及0 · 1 2 8 g之雄激素及〇 . 〇 4 g之硬脂酸酯，乾 燥黏著藥劑層爲含有8 5 · 8重量％之丙烯系黏著劑與2 • 5重量％之山梨聚糖單月桂酸酯與7 · 5重量％之甘油 與3 · 2重量％之雄激素與1重量％之硬脂酸鎂者。試驗 結果如表7所示。 實施例3〇 與實施例1 2同法進行後，製備膠帶製劑。 惟’黏著藥劑用塗佈液爲含1 4 · 0 g之丙烯系黏著 劑與0 · 1 g之山梨聚糖單月桂酸酯與〇 · 3 g之甘油及 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） (請先閲讀背面之注意事項再填寫本頁) •裝·i 'Explanation of invention (42) [Note] SPAN 2 0 SPAN 8 0 SPAN 8 5 GCS t M g Tween 20 Tween 4 0 Tween 6 0 I PM I〇P A7 B7 Sorbitan monolaurate Sorbitan single oil Ester sorbitan trioleate glycerol magnesium stearate polyoxyethylene sorbitan monolaurate polyoxyethylene sorbitan monopalmitate polyoxyethylene sorbitan monostearate isopropyl nutmeg Ester isooctyl palmitate In Examples 25 below, the cohesive force and moisture permeability of the adhesive agent layer containing the drug are considered for the permeability when Feldack is used as a non-steroidal anti-inflammatory painkiller instead of clodrophene. have a discussion. Example 25 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent contains 6.4 g of a propylene-based adhesive and 0.1 g of sorbitan monolaurate and 0.3 g of glycerol and 0.04 g of felvinack and 0. · For 0.4 g of magnesium stearate, the dry Z-adhesive drug layer contains 8 8 · 5% by weight of propylene-based adhesive and 2.5% by weight of sorbitan monolaurate, 7.5% by weight Of glycerol and 0.5% by weight of felvinack and 1% by weight of magnesium stearate. The test results are shown in Table 5. This paper size applies Ningguo National Standard (CNS) A4 (210X 297 mm) (Please read the precautions on the back before filling this page) D-45 552143 A7 B7 V. Description of the invention (43) Reference example 3 celtach The anti-inflammatory patch (trademark, patch) is the same as that in Example 25 and is used for the felvinac penetration test and cohesion test. The test results are shown in Table 5. Table 5 Permeability of additive felvinac (β g / cm2 * 24hr) Cohesion and moisture permeability (g / m2 · day) Example 25 SPAN20 2.5wt% GC 7.5 // StMg l.〇 // 4.2 Good 722 Reference example 3 ce 11 ach anti-inflammatory patch (trademark) 4.0 Good sleep note] SPAN 2 0 ·· Sorbitan monolaurate GC: Glycerin S t M g: Magnesium stearate In the following Examples 2 6 and 27, estrogen As the estrogen permeability of the adhesive agent layer when used as a female hormone agent, the cohesiveness and moisture permeability of the adhesive agent layer containing the agent will be discussed. In addition, in order to achieve a highly permeable estrogen, the following examples 2 and 8 are added with ethyl oleate and polyvinylpyridine. The paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm). (Please read the back Note: Please fill in this page again.) Packing. Printed by the Intellectual Property Bureau of the Ministry of Economic Affairs and printed by the Consumer Cooperatives of the Ministry of Economic Affairs-46- 552143 A7 B7 V. Description of Invention (44) The same discussion is also made in the pyrrolidone series. Example 2 6 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer contains 14 · 0 g of a propylene-based adhesive and 0.1 · g of sorbitan monolaurate, and 0.3 g of glycerol and 0 · 128 g of estrogen and 〇. 〇4g of magnesium stearate is a dry adhesive agent layer containing 75.8% by weight of propylene-based adhesive and 2.5% by weight of sorbitan monolaurate and 7 _5% by weight Glycerin with 3.2% by weight of estrogen and 1% by weight of magnesium stearate. The test results are shown in Table 6. Example 2 7 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of 14 · 0 g of a propylene-based adhesive and 0 -1 g of sorbitan monolaurate, 0.3 g of glycerin, and 0.4 g of isopropyl meat. Myristate with 0.128 g of estrogen and 0.004 g of magnesium stearate. The dried adhesive agent layer was 75. 8% by weight of a propylene-based adhesive and 2.5% by weight of sorbitan monolaurate and 7.5% by weight of glycerol and 10% by weight of isopropyl myristic acid. Ester and 3.2% by weight of estrogen and 1% by weight of stearic acid. The test results are shown in Table 6. Example 2 8 This paper size applies the Chinese National Standard (CNS) a4 specification (2i0X 297 mm) (Please read the precautions on the back before filling out this page}. Binding and printing by the Intellectual Property Bureau of the Ministry of Economic Affairs, Consumer Consumption Cooperatives -47- 552143 Μ —----- Β7 _ V. Description of the invention (45) The tape preparation was prepared after the same method as in Example 12. (Please read the precautions on the back before filling in this page) However, the adhesive The coating solution for the drug layer is composed of 8.3 g of an propylene-based adhesive, 0.2 g of sorbitan monolaurate, 0.4 g of diisopropyl myristate, and 0.6 g of 1 2,6-hexanetriol and 0.6 g of ethyl oleate and 0.24 g of polyvinylpyrrolidone with 0.16 g of estrogen and 0.4 g of magnesium stearate, The dried adhesive agent layer contains 45% by weight of a propylene-based adhesive and 5% by weight of sorbitan monolaurate and 10% by weight of isopropyl myristate and 15% by weight of 1,2, 6-hexanetriol and 15% by weight ethyl oleate and 6% by weight polyvinylpyrrolidone and 4% by weight estrogen and 1% by weight stearic acid Magnesium. The test results are shown in Table 6. Comparative Example 21 and Example 12 were performed in the same manner to produce a tape preparation. Printed by the Wisconsin Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, but the coating solution for the adhesive agent contains 17.7 g of propylene-based adhesive, 0.18 g of estrogen, and 0.44 g of magnesium stearate were dried adhesive layers containing 95.8% by weight of propylene-based adhesive Agent with 3.2% by weight of estrogen and 1% by weight of magnesium stearate. The visual inspection results are shown in Table 6. The paper size applies to the Chinese National Standard (CNS) A4 (210X297 mm)- 48- 552143 Μ B7 V. Description of the invention (46) Table 6 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs \ Additive estrogen estradiol Permeability (ng / cm2. 48hr) Cohesion (Prevention of adhesion and residue on the adhesive layer) Moisture permeability (g / m2 *) Example 26 SPAN20 2.5wt% 20 〇724 GC 7.5 // StMg 1.0 // 27 SPAN20 2.5wt% 15.7 〇716 GC 2.5 // IPM 10 // StMg 1.0 // 28 SPAN20 5wt % 35 〇720 IPM 10 〃 1,2,6- 15 // 1,2,6- Hexatriol 〇E 15 〃 PVP 6 f StMg // Comparative Example 21 StMg 1.0 // 1.1 〇515 [Note] SPA Ν 2 0: Sorbitan monolaurate (Please read the precautions on the back before filling in this page ) This paper size applies Chinese National Standard (CNS) A4 specification (210X 297 mm) -49- 552143 A7 B7 i. Description of the invention (47) GC: glycerol S t M g: magnesium stearate IPM: isopropyl meat Myristate 0 E: Ethyl oleate P vp: Polyvinylpyrrolidone In Examples 2-9 to 30 below, regarding the permeability when androgen is used as a male hormone, the cohesive force of the adhesive agent layer containing the agent and The moisture permeability is discussed. Example 2 9 was performed in the same manner as in Example 12 to produce a tape preparation. However, the coating solution for the adhesive agent layer was composed of i 5 · 9 g of a propylene-based adhesive and 0 · 1 g of sorbitan monolaurate and 0.3 g of glycerol and 0 · 1 2 8 g of androgen. And 0.04 g of stearic acid ester, and the dry adhesive agent layer contains 8 5 · 8% by weight of a propylene-based adhesive and 2 · 5% by weight of sorbitan monolaurate and 7.5% by weight of Glycerin and 3.2% by weight of androgens and 1% by weight of magnesium stearate. The test results are shown in Table 7. Example 30 After performing the same method as in Example 12, a tape preparation was prepared. However, the coating solution for the adhesive agent contains 14 · 0 g of propylene-based adhesive and 0.1 · g of sorbitan monolaurate and 0.3 g of glycerin, and this paper standard is applicable to Chinese national standards (CNS ) A4 size (210X 297mm) (Please read the precautions on the back before filling this page) • Installation ·

、1T 經濟部智慧財產¾員工消費合作社印製 -50- 552143 A7 B7 五、發明説明（48) 〇 ·4g之異丙基肉豆蔻酸酯與〇·128g之雄激素及 〇 . 0 4 g之硬脂酸鎂者，乾燥之黏著藥劑層爲含有 7 5 · 8重量％之丙烯系黏著劑與2 · 5重量％之山梨聚 糖單月桂酸酯及7·5重量％之甘油與1〇重量％之異丙 基肉豆蔻酸酯與3.2重量％之雄激素及1重量％之硬脂 酸鎂者。試驗結果如表7所示。 比較例2 2 與實施例1 2同法進行後製造膠帶製劑。 惟，黏著藥劑用塗佈液爲含1 7 · 7 g之丙烯系黏著 劑與0 · 128g之雄激素及〇 · 〇4g之硬脂酸鎂者、 乾燥之黏著藥劑層爲9 5 · 8重量％之丙烯系黏著劑與 3 · 2重量％之雄激素及1重量％之硬脂酸鎂者。試驗結 果如表7所示。 (請先閲讀背面之注意事項再填寫本頁} 經濟部智慧財產局員工消費合作社印製 衣紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -51 - 552143 A7 B7 五、發明説明（49) 表 7 ΪΧ 添加劑 雄激素 滲透量 (β g/cm2* 48hr) 凝集力（黏 著藥劑層之 附著殘留防 止性） 透濕度 (g/m2· 曰） 實施例 29 SPAN20 2.5 wt% 5.1 〇 752 GC 7.5 // StMg 1.0// 30 SPAN20 2.5 wt% 6.2 〇 734 GC 7.5// IPM 10 // StMg 1.0 〃 比較例 22 StMg 1.0// 2.5 〇 485 (請先閱讀背面之注意事項再填寫本頁)1, 1T Intellectual Property of the Ministry of Economics ¾ Printed by employee consumer cooperatives -50- 552143 A7 B7 V. Description of the invention (48) 0.4 g of isopropyl myristate and 0.82 g of androgen and 0.4 g of hard For magnesium stearate, the dried adhesive agent layer is composed of 7.5 · 8% by weight of propylene-based adhesive and 2.5% by weight of sorbitan monolaurate and 7.5% by weight of glycerol and 10% by weight. Isopropyl myristate and 3.2% by weight of androgens and 1% by weight of magnesium stearate. The test results are shown in Table 7. Comparative Example 2 2 was performed in the same manner as in Example 12 to produce a tape preparation. However, if the coating solution for an adhesive agent is a propylene-based adhesive agent containing 11.7 g, androgen in an amount of 0.128 g, and magnesium stearate in an amount of 0.44 g, the dried adhesive agent layer is 95. 8% by weight. A propylene-based adhesive and 3.2% by weight of androgens and 1% by weight of magnesium stearate. The test results are shown in Table 7. (Please read the precautions on the back before filling out this page} The size of the printed paper used by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) -51-552143 A7 B7 V. Description of the invention (49) Table 7 Ϊχ additive androgen penetration (β g / cm2 * 48hr) Cohesion (prevention of adhesion and adhesion of the adhesive agent layer) Moisture permeability (g / m2 ·) Example 29 SPAN20 2.5 wt% 5.1 〇752 GC 7.5 // StMg 1.0 // 30 SPAN20 2.5 wt% 6.2 〇734 GC 7.5 // IPM 10 // StMg 1.0 〃 Comparative Example 22 StMg 1.0 // 2.5 2.5 〇485 (Please read the precautions on the back before filling this page)

經濟部智慧財產局8工消費合作社印製 表2〜7代表本發明膠帶製劑之黏著藥劑層具有良好 之凝聚力（防止附著殘留劑）、剝離強度、透濕性等，表 3〜7係代表本發明黏著藥劑具有良好之藥劑滲透性（經 皮吸收性）者。 產業上可利用性 本發明黏著劑組成物及膠帶具有良好之黏著性與透濕 性’又，本發明黏著性藥劑組成物及膠帶製劑具有良好之 黏著性及透濕性，更具有良好之藥劑滲透性（經皮吸收性 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -52- 552143 A7 B7 五、發明説明（5〇) )，可使無刺激皮膚之有效藥劑經皮吸收。因此，本發明 黏著劑組成物、膠帶、黏著性藥劑組成物及膠帶製劑可有 上 業 產 於 用 利 效 ---------裝-- (請先閎讀背面之注意事項再填寫本頁) 、11 線 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -53 -Tables 2 ~ 7 printed by the 8th Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs represent that the adhesive agent layer of the tape preparation of the present invention has good cohesion (prevention of residual agents), peel strength, moisture permeability, etc. Tables 3 ~ 7 are representative of this Invented adhesive agents have good drug permeability (percutaneous absorption). Industrial Applicability The adhesive composition and the tape of the present invention have good adhesion and moisture permeability. Moreover, the adhesive agent composition and the tape preparation of the present invention have good adhesion and moisture permeability, and have better medicaments. Permeability (Transdermal Absorptivity) This paper is sized to the Chinese National Standard (CNS) A4 (210X297 mm) -52- 552143 A7 B7 V. Description of the invention (50)), which can effectively percutaneously stimulate the skin without irritation absorb. Therefore, the adhesive composition, adhesive tape, adhesive agent composition and adhesive tape preparation of the present invention may have beneficial effects produced by the industry --------- packing-(Please read the precautions on the back before reading) (Fill in this page), printed by the Consumers' Cooperative of the Intellectual Property Bureau of the 11th Ministry of Economic Affairs, this paper is printed in accordance with China National Standard (CNS) A4 (210X 297 mm) -53-

Claims (1)

經濟部智慧財產局員工消費合作社印製 552143 A8 B8 C8 一 —_ D8 六、申請專利範圍 2 異之脂肪酸酯、及聚乙烯吡咯烷酮。 4 ·如申請專利範圍第3項之黏著劑組成物，其中該 含有多價醇之液體成份中之脂肪酸酯含量對組成物總量而 言爲1〜3 0重量％者。 5 ·如申請專利範圍第3項之黏著劑組成物，其中， 該脂肪酸酯係選自肉豆蔻酸異丙酯、棕櫚酸異丙酯、棕櫚 酸異辛酯、油酸乙酯、及癸二酸二乙酯者。 6 . —種透濕性膠帶，其特徵係具有支撑體、與形成 於其中一表面上，且含有如申請專利範圍第1〜5項中任 一項之黏著劑組成物之黏著層者。 7 .如申請專利範圍第6項之透濕性膠帶，其中，具 有3 0 0〜8 0 0 g/m 2 ·日以上之透濕度者。 8 .如申請專利範圍第6項之透濕性膠帶，其中，該 黏著層爲具有5〜1 0 0 0 //m厚度者。 9 · 一種黏著性藥劑組成物，其特徵係含有如申請專 利範圍第1〜5項中任一項之黏著劑組成物，與對該粘著 性組成物重量而言爲0 · 0 5〜4 0重量％之選自非類固 醇類消炎鎭痛劑、抗高血壓劑、局部麻醉劑、抗生素、鈣 拮抗劑、強心劑、抗癲癎劑、降壓利尿劑、抗真菌劑、抗 過敏•抗組織胺劑、抗惡性腫瘤劑、抗精神病劑、抗暈眩 劑、睡眠調節劑、冠狀血管擴張劑、激素劑、降壓劑、氣 喘治療劑、鼻炎治療劑、降血糖劑、及抗潰瘍劑者。 1 0 . —種膠帶製劑，其特徵爲具有支撐體·，與形成 於其中一表面上，且含有如申請專利範圍第9項之含黏著 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） I 訂 I I線 (請先閱讀背面之注意事項再填寫本頁} -55 - 552143 A8 B8 C8 D8 六、申請專利範圍3 中 其 劑 製 帶 膠 之 項 ο ο -—1 者第 層圍 劑範 藥利 著專 黏請 之申 物如 成· 組 劑 藥 性 1—1 一—1 有 具 黏 該 \ 範 一 利 5 ο 專有 ο 請具 8 申爲 一 如層 ο •劑 ο 2 藥 3 1 著 m IX πυ 第 ο 圍 一—I 上 以 曰 中 。其 者，。 度劑者 yl製度 0帶厚 β 膠之 之m 項 “ ο ο (請先閲讀背面之注意事項1^1寫本頁) 經濟部智慧財產局員工消費合作社卬製 -56 - 民國91年12月3日修' 第88112931號專利申^^ 中文說明書修正本丨& ν'; 申請曰期 88年 7月29日 案 號 88112931 類 別 /) 1< ^/φ XPrinted by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 552143 A8 B8 C8 I —_ D8 VI. Patent Application Scope 2 Aliphatic fatty acid esters and polyvinylpyrrolidone. 4. The adhesive composition according to item 3 of the patent application, wherein the fatty acid ester content of the polyvalent alcohol-containing liquid component is 1 to 30% by weight based on the total amount of the composition. 5. The adhesive composition according to item 3 of the application, wherein the fatty acid ester is selected from the group consisting of isopropyl myristate, isopropyl palmitate, isooctyl palmitate, ethyl oleate, and decyl Diethyl diacid. 6. A kind of moisture-permeable tape, which is characterized by having a support body and an adhesive layer formed on one of the surfaces and containing an adhesive composition as in any one of claims 1 to 5 of the scope of patent application. 7. The moisture-permeable tape according to item 6 of the scope of patent application, wherein the moisture-permeable tape has a moisture permeability of 300 to 800 g / m 2 · day. 8. The moisture-permeable tape according to item 6 of the patent application scope, wherein the adhesive layer has a thickness of 5 to 1 0 0 0 // m. 9 · An adhesive pharmaceutical composition, characterized in that it contains an adhesive composition as in any of claims 1 to 5 of the scope of patent application, and the weight of the adhesive composition is 0 · 0 5 to 4 0% by weight selected from non-steroidal anti-inflammatory painkillers, antihypertensive agents, local anesthetics, antibiotics, calcium antagonists, cardiotonics, antiepileptics, antihypertensive diuretics, antifungals, antiallergic and antihistamines Agents, anti-malignant agents, antipsychotics, anti-dizziness agents, sleep regulators, coronary vasodilators, hormones, antihypertensive agents, asthma therapeutic agents, rhinitis therapeutic agents, hypoglycemic agents, and antiulcer agents. 1. A kind of tape preparation, which is characterized by having a support, and formed on one of the surfaces, and contains the adhesive with the paper size as in item 9 of the patent application. The standard of this paper is applicable to China National Standard (CNS) A4 (210X297). Mm) I order II line (please read the precautions on the back before filling out this page) -55-552143 A8 B8 C8 D8 VI. The scope of the patent application 3 for the adhesive tape made by the agent ο-1 of the first layer The application of the adjuvant Fan Yaoli is as follows. The composition of the application is 1: 1. The medicine is 1-1. -1 is sticky. \ Fan Yili 5 ο Proprietary ο Please apply for 8 as a layer ο • Agent ο 2 Medicine 3 1 with m IX πυ No. ο Wai Yi — I above and said. The other,. Pharmacy system yl system 0 with thick β glue of the m term "ο ο (Please read the precautions on the back 1 ^ 1 first (Write this page) The Employee Cooperative Cooperative System of the Intellectual Property Bureau of the Ministry of Economic Affairs -56-Revised 'No. 8812931 patent application on December 3, 1991 ^^ Chinese version of the revised manual 丨 &ν'; Application date July 88 Case No. 8812931 Category /) 1 < ^ / φ X A4 C4 552143 (以上各欄由本局填註） 當|專利説明書 發明々广 …新型德 中 文 黏箸性組成物、以及含此組成物之透濕性膠帶、黏箸性藥劑組成物 及膠帶製劑 英 文 ADHESIVE COMPOSITION, AND MOISTURE-PERMEABLE ADHESIVE TAPE, ADHESIVE MEDICAL COMPOSITION AND ADHESIVE MEDICAL TAPE CONTAINING SAME 姓 名 (1)北囿英一 0 峯松宏昌 ⑶川口武行 fk 二、雜 鋪作 人 國 籍 住、居所 姓 名 (名稱） (1)日本國山口縣岩國市日出町二番一號 司岩國研究Ψ心rt 0 日本國山口縣岩國市日出町二番一號 司岩國研究中心内 (¾ 日本國山口縣岩國市日出町二番一號 司岩國研究中心内 (1)帝人股份有限公司 帝人 帝人股份有限公 帝人股份有限公 帝人股份有限公 裝 訂 [： 申讀人 國 籍 住、居所 (事務所） 代表人 姓 名 (1)日本 (1)日本國大阪府大阪市中央區南本町一丁目六番七號 (1)安居祥策 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） 線 552143A4 C4 552143 (The above columns are filled by this bureau.) When | Patent specification invention wide ... New German-Chinese adhesive composition, and moisture-permeable tape, adhesive pharmaceutical composition and adhesive tape preparation containing this composition English ADHESIVE COMPOSITION, AND MOISTURE-PERMEABLE ADHESIVE TAPE, ADHESIVE MEDICAL COMPOSITION AND ADHESIVE MEDICAL TAPE CONTAINING SAME (1) Inside the Iwakuni Research Center, No.1, Hijimachi, Iwakuni, Iwakuni, Yamaguchi, Japan 0 Inside the Iwakuni Research Center, No.1, Hijimachi, Iwakuni, Iwakuni, Japan (1) Teijin Co., Ltd. Teijin Teijin Co., Ltd. Teijin Co., Ltd. Teijin Co., Ltd. Limited public binding [[Applicant's nationality residence, residence (office) Representative name (1) Japan ( 1) No.7, Ichime-chome, Minamimotocho, Chuo-ku, Osaka, Osaka, Japan (1) Anju Shoji Paper The scale is applicable to China National Standard (CNS) A4 specification (210X297 mm) line 552143 六、申請專利範圍1 1 · 一種黏著劑組成物，其特徵爲含有5 0〜9 0重 量％之丙烯系黏著劑，與2 · 5〜5 0重量％之含有多價 醇之液體成份，以及〇·〇1〜1〇重量％之含8〜18 個碳原子之烴基的脂肪酸與1〜3價之金屬所成之脂肪酸 金屬鹽者， 該丙烯系黏著劑係含有一種以上選自丙烯酸、甲基丙 烯酸、丙烯酸烷酯、甲基丙烯酸烷酯之各聚合物，及含至 ? 少1種此等的共聚物， I 該含有多價醇之液體成份中之多價醇係選自，甘油、 I丙二醇、1，3 — 丁二醇、二甘油、二丙二醇、1，2, ' 6 -己三醇、山梨糖醇、聚乙二醇及季戊四醇， 4 f 該脂肪酸金屬鹽中具有含8〜1 8個碳原子之烴基的 f i脂肪酸係選自月桂酸、肉豆蔻酸、硬脂酸及油酸，該1〜 ·’. 3價金屬係選自鈉、鎂、鋅及鋁， 該含有多價醇之液體成分係，除該多價醇之外，含有 對全體組成物而言爲〇 · 5〜2 0重量份含量之至少一種 選自具有含12〜18個碳原子之烴基的脂肪酸之山梨聚 '糖酯’及聚氧化烯山梨聚糖酯之山梨聚糖酯化合物者。 2 ·如申請專利範圍第1項之黏著劑組成物，其中， 該含有多價醇之液體成份中之多價醇含量係對組成物總重 量而言爲1〜3 0重量％者。 3 ·如申請專利範圍第χ項之黏著劑組成物，其中該 含有多價醇之液體成份爲，除該多價醇及該山梨·聚糖酯化 合物之外，尙含有至少1種選自與該山梨聚糖酯化合物相 本紙張尺度適用中國國家標準（CNS ) A4規格（210 X 297公釐） (請先閲讀背面之注意事項再填寫本頁)6. Scope of patent application 1 1 · An adhesive composition characterized by containing 50 to 90% by weight of a propylene-based adhesive, and 2.5 · 50 to 50% by weight of a liquid component containing a polyvalent alcohol, and 〇1 ～ 10 ％ by weight of a fatty acid metal salt composed of a hydrocarbon group fatty acid containing 8 to 18 carbon atoms and a metal having 1 to 3 valences, and the propylene-based adhesive contains one or more selected from acrylic acid and formic acid. Polymers of acrylic acid, alkyl acrylate, and alkyl methacrylate, and copolymers containing at least one of these, I The polyvalent alcohol in the liquid component containing the polyvalent alcohol is selected from the group consisting of glycerin, I propylene glycol, 1,3-butanediol, diglycerol, dipropylene glycol, 1,2, 6-hexanetriol, sorbitol, polyethylene glycol, and pentaerythritol, 4 f The fatty acid metal salt contains 8 ~ The 18-carbon hydrocarbon-based fi fatty acid is selected from lauric acid, myristic acid, stearic acid, and oleic acid, and the 1 to · '. The trivalent metal system is selected from sodium, magnesium, zinc, and aluminum, and the The liquid component of the valence alcohol contains, in addition to the polyhydric alcohol, the content of the entire composition is 0. 5 to 20 parts by weight of at least one selected from the group consisting of sorbitan poly'sugar esters' having fatty acids containing 12 to 18 carbon atoms, and polyoxyalkylene sorbitan esters of sorbitan ester compounds. 2. The adhesive composition according to item 1 of the scope of patent application, wherein the polyvalent alcohol content of the polyvalent alcohol-containing liquid component is 1 to 30% by weight based on the total weight of the composition. 3. The adhesive composition according to item χ of the patent application range, wherein the liquid component containing the polyvalent alcohol is, in addition to the polyvalent alcohol and the sorbitan polysaccharide ester compound, rhenium contains at least one selected from the group consisting of The sorbitan ester compound is based on the Chinese paper standard (CNS) A4 (210 X 297 mm). (Please read the precautions on the back before filling this page) 經濟部智慧財產局員工消費合作社印製 -54-Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs -54-
TW088112931A 1998-07-29 1999-07-29 Adhesive composition, and moisture-permeable adhesive tape, adhesive medical composition and adhesive medical tape containing same TW552143B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21405898 1998-07-29
JP29197198 1998-10-14

Publications (1)

Publication Number Publication Date
TW552143B true TW552143B (en) 2003-09-11

Family

ID=26520122

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088112931A TW552143B (en) 1998-07-29 1999-07-29 Adhesive composition, and moisture-permeable adhesive tape, adhesive medical composition and adhesive medical tape containing same

Country Status (12)

Country Link
US (1) US6797280B1 (en)
EP (1) EP1148106B1 (en)
KR (1) KR20010071049A (en)
CN (1) CN1320145A (en)
AT (1) ATE283040T1 (en)
AU (1) AU748591B2 (en)
CA (1) CA2338987A1 (en)
DE (1) DE69922257T2 (en)
HK (1) HK1040090B (en)
NZ (1) NZ509655A (en)
TW (1) TW552143B (en)
WO (1) WO2000006659A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10032537A1 (en) * 2000-07-05 2002-01-31 Labtec Gmbh Dermal system containing 2- (3-benzophenyl) propionic acid
JP4799778B2 (en) * 2001-08-23 2011-10-26 日東電工株式会社 Medical pressure-sensitive adhesive composition and pressure-sensitive adhesive tape or sheet using the composition
US7223468B2 (en) * 2003-11-06 2007-05-29 Nitto Denko Corporation Medical pressure-sensitive adhesive sheets and method for producing the same
US7915338B2 (en) * 2005-12-28 2011-03-29 3M Innovative Properties Company Adhesive with alkanoate blend
JP5020554B2 (en) * 2006-06-29 2012-09-05 ライオン株式会社 Non-aqueous adhesive composition and patch using the same
BRPI0720996B8 (en) * 2006-12-20 2021-06-22 Coloplast As pressure sensitive adhesive composition containing salt, layered adhesive construct, and medical device
JP4322926B2 (en) * 2007-01-23 2009-09-02 本田技研工業株式会社 Control device for automatic transmission for vehicle
JP5313868B2 (en) 2007-03-02 2013-10-09 テイカ製薬株式会社 Transdermal absorption pharmaceutical composition, pharmaceutical composition storage unit, and transdermal absorption preparation using the same
BRPI0907199A2 (en) 2008-01-10 2015-07-14 Coloplast As Pressure sensitive adhesive composition comprising water-soluble compound and layered adhesive construction and medical device comprising the same
JP2010285548A (en) * 2009-06-11 2010-12-24 Nitto Denko Corp Adhesive tape for optical member
US20110178203A1 (en) * 2009-10-19 2011-07-21 Elmer's Products, Inc. High strength glue formulation
WO2016127020A1 (en) * 2015-02-06 2016-08-11 Noven Pharmaceuticals, Inc. Pressure-sensitive adhesives for transdermal drug delivery
US20210191267A1 (en) * 2016-03-16 2021-06-24 Toyobo Co., Ltd. Water-developable photosensitive resin composition for flexographic printing and photosensitive resin original plate for flexographic printing obtained therefrom
RU2764443C2 (en) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene
EP3558275A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3079697A1 (en) * 2017-10-11 2019-04-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive
JP7112256B2 (en) * 2018-06-08 2022-08-03 株式会社日本触媒 Adhesive composition and its use
MX2020014286A (en) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6112621A (en) 1984-06-27 1986-01-21 Lion Corp Cataplasma
US5296230A (en) 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
GB8600599D0 (en) * 1986-01-10 1986-02-19 Lingner & Fischer Gmbh Composition
JP2509585B2 (en) 1986-10-21 1996-06-19 帝國製薬株式会社 External patch
JPS63230640A (en) 1987-03-19 1988-09-27 Shiseido Co Ltd Transcutaneous absorbefacient and external drug for skin containing said absorbefacient
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH07116025B2 (en) * 1988-03-11 1995-12-13 積水化学工業株式会社 Patch
JPH07103016B2 (en) 1988-03-11 1995-11-08 積水化学工業株式会社 Patch and method for producing the same
JPH02196714A (en) 1989-01-26 1990-08-03 Sekisui Chem Co Ltd Spreading plaster of percutaneous absorption
JPH0780772B2 (en) 1989-03-07 1995-08-30 積水化学工業株式会社 Transdermal formulation
JP2748024B2 (en) * 1989-07-05 1998-05-06 株式会社サクラクレパス Removable solid glue
JP2700835B2 (en) 1989-12-28 1998-01-21 日東電工株式会社 Acrylic gel material and acrylic gel preparation
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
JPH04266742A (en) * 1991-02-21 1992-09-22 Sekisui Chem Co Ltd Medical conducting adhesive
EP0607434B1 (en) 1991-08-30 1999-01-27 Hisamitsu Pharmaceutical Co., Inc. Anti-inflammatory analgesic plaster
JP3515613B2 (en) * 1994-07-14 2004-04-05 昭和電工株式会社 Heat-resistant heat-sensitive adhesive and multilayer laminate using the adhesive
KR100191062B1 (en) 1994-09-16 1999-06-15 나카토미 히로타카 A preparation for external use and a patch having the preparation attached thereto
JP3715361B2 (en) 1995-11-21 2005-11-09 三笠製薬株式会社 Transdermal adhesive composition and process for producing the same

Also Published As

Publication number Publication date
HK1040090A1 (en) 2002-05-24
EP1148106A1 (en) 2001-10-24
CN1320145A (en) 2001-10-31
AU748591B2 (en) 2002-06-06
DE69922257D1 (en) 2004-12-30
KR20010071049A (en) 2001-07-28
WO2000006659A1 (en) 2000-02-10
EP1148106A4 (en) 2003-06-18
EP1148106B1 (en) 2004-11-24
CA2338987A1 (en) 2000-02-10
AU4802599A (en) 2000-02-21
NZ509655A (en) 2002-09-27
ATE283040T1 (en) 2004-12-15
DE69922257T2 (en) 2005-11-10
HK1040090B (en) 2005-04-01
US6797280B1 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
TW552143B (en) Adhesive composition, and moisture-permeable adhesive tape, adhesive medical composition and adhesive medical tape containing same
TWI236916B (en) Ultraviolet-shielding adhesive preparation
JP2700835B2 (en) Acrylic gel material and acrylic gel preparation
TW200300095A (en) Plaster having laminated support
TWI233810B (en) A paster sheet
JP2004174202A (en) Plaster
TW200800291A (en) Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
JP4199485B2 (en) Patch
JP4430120B2 (en) Antimycotic patch
TWI415636B (en) Bisoprolol transdermal device
JP2000044904A (en) Acrylic pressure-sensitive adhesive tape and transdermal formulation
JPS6393714A (en) Plaster for transcutaneous absorption
EP0531938B1 (en) Acrylic gel material and gel-based medical preparation for percutaneous absorption employing the same
JP4799783B2 (en) Elastic patch
JP4744439B2 (en) Patch
JP5025998B2 (en) Transdermal absorption preparation
WO2003062342A1 (en) Pressure-sensitive adhesive and patch employing the same
JPH0623029A (en) Acrylic gel material and acrylic gel preparation
JP2688778B2 (en) Patch for disease treatment
JPS63313723A (en) External cataplasm
TWI700103B (en) Patch
JPH10306023A (en) Percutaneously absorbable preparation and its production
JPH0565224A (en) Gelatinous material and therapeutic gel pharmaceutical using the same
JPH07165563A (en) Tape pharmaceutical preparation
JP2003210566A (en) Method of manufacturing adhesive molding mainly composed of crosslinked polymer

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees